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SH2 scr homology 2
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STAT signal transducer and activators of transcription
TF tissue factor
TGF-α -β transforming growth factor alpha, beta
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growth factor homology domains
Tek tunica interna endothelial cell kinase
TK tyrosine kinase
TIMP-1, -2 tissue inhibitor of metalloproteinases -1, -2
TNF-α tumor necrosis factor alpha
VEGF vascular endothelial growth factor
VEGFR VEGF receptor(s 1, 2, 3)
VPF vascular permeability factor
u-PA urokinase plasminogen activator
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5INTRODUCTION
The cardiovascular system is the first organ system to start functioning in the embryo and it consists of
endothelial cells, pericytes/smooth muscle cells and cardiac myocytes. The circulatory network includes
the blood and lymphatic vasculature. The endothelial cells lining the primitive vascular plexus are formed
from angioblasts, differentiated from mesenchymal cells in a process called vasculogenesis, mainly
restricted to the embryonic period. Development of the vascular tree is followed by a process called
angiogenesis, which is the sprouting or splitting of blood vessels from pre-existing vessels. This occurs
during embryonic development (Risau, 1995), as well as in adult life, for instance during wound healing
(Knighton et al., 1983) or neovascularization of tumors (Folkman, 1985).
The lymphatic vessels develop after the blood circulation starts functioning and they derive from embryonic
veins (Clark and Clark, 1937). Lymphangiogenesis occurs during organogenesis. Adult lymphatics are able
to regenerate by sprouting from pre-existing lymphatic vessels (Clark and Clark, 1932).
One of the many signaling pathways thought to function in the regulation of physiological and pathological
angiogenesis is formed by the vascular endothelial growth factor (VEGF) family acting through endothelial
specific receptor tyrosine kinases, the vascular endothelial growth factor receptors (VEGFRs).
The present study is undertaken to identify and to characterize the specific roles of VEGF, VEGF-B,
VEGF-C and VEGF-D in vivo, during embryonic development and in adult tissues. The goal is approached
by analysing the expression patterns of these growth factors and their specific receptors at the mRNA and
protein level, using primarily in situ hybridization techniques accompanied by immunohistochemistry in
some cases. The expression of VEGF, VEGF-B and VEGF-C is studied in some tumors to further
investigate their possible involvement in tumor angiogenesis. VEGFR-3 expression is studied in
lymphangiomatosis a disorder thought to result from overproliferation of the lymphatic endothelium.
6REVIEW OF THE LITERATURE
1. Vasculogenesis, angiogenesis and lymphangiogenesis
1.1. Vasculogenesis
The first step in the sequence of events leading to the formation of the embryonic vasculature is the
induction of the ventral-lateral mesoderm, by members of the fibroblast growth factor (FGF) and
transforming growth factor-beta (TGF-β) families (Weinstein, 1999). The ventral-lateral mesoderm gives
rise to cardiac, pronephric, hematopoietic and vascular endothelial tissues (Weinstein, 1999).
Vasculogenesis begins by a process of in situ differentiation of hemangioblasts from mesoderm and
formation of cellular aggregates or blood islands which then interconnect (Carmeliet and Collen, 1999).
The cells in the periphery differentiate into early endothelial cells, whereas the central cells become
hematopoietic cells (Flamme and Risau, 1992). Vasculogenesis proceeds into a second phase in which
endothelial cells invade, fuse and become assembled into a primitive capillary plexus (See Figure 2 and
Risau, 1997). The vascularization events intra-embryonally follow those of the yolk sac (See Figure 1). The
blood vessels, which differentiate inside the embryo are connected to the yolk sac by the vitelline arteries
and veins, which develop within the embryo (Wang et al., 1992). The primitive capillaries are established
by intracellular lumen formation which occurs by endothelial vacuolization or by intercellular lumen
formation which happens through joining of distal endothelial cells to a pre-existing lumen (Carmeliet and
Collen, 1999). Studies of mutant mice reveal the importance of VEGF (Carmeliet et al., 1996; Ferrara et
al., 1996), VEGFR-2 (Shalaby et al., 1995), fibronectin (George et al., 1993), the α5 integrin receptor
(Yang et al., 1993), and TGF-β1 (Dickson et al., 1995) in the control of vasculogenesis. VEGFR-1 has a
primary role in regulation of hemangioblast development (Fong et al., 1999) and VEGFR-1 gene
inactivation results in abnormal development of the vasculature (Fong et al., 1995). The larger vessels of
the embryo and the primary vascular plexus in the lung, the pancreas, the spleen, the heart and the yolk
sac arise by the second phase of vasculogenesis (Wilting and Christ, 1996). Vasculogenesis which is
mainly restricted to embryonic development may occur also in adult species, a suggestion supported by
the finding that circulating angioblasts in the human peripheral blood are able to in vitro differentiate into
endothelial cells (Asahara et al., 1997).
7Fig.1.  Mouse embryo within the uterus. The extra-embryonic membranes amnion, yolk sac and Reichert´s
membrane are shown.
1.2. Vasculogenesis associated hematopoiesis
Vasculogenesis and hematopoiesis seem to proceed in concert. These events take place extra-
embryonally in the yolk sac as well as intra-embryonally in the trunk intermediate cell mass (ICM) (Al-
adhami and Kunz, 1977) and later in the AGM (aorta-gonad-mesonephros), liver and bone marrow
(Weinstein, 1999; Medvinsky et al., 1993). The early vascular endothelial cells which have not yet formed a
lumen and the hematopoietic cells formed from mesoderm, appear to be intimately associated. This close
proximity appears during early ontogeny of the vertebrate blood system and is one of the indications for
the existence of the common precursor cell, the “hemangioblast” (Sabin, 1920; Murray, 1932; Wagner,
1980). Other indications are the defects in both the hematopoietic and angioblastic lineages in embryos
lacking VEGFR-2 (Shalaby et al., 1995). VEGFR-2 is one of the genes which are co-expressed and/or
required during early stages of both blood cell and vessel development (Matthews et al., 1991; Millauer et
heart
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8al., 1993; Yamaguchi et al., 1993). Additionally, angioblasts and hematopoietic stem cells share certain
antigenic determinants including Tie-1, Tie-2, and CD34 (Flamme and Risau, 1992; His et al., 1900; Weiss
and Orkin, 1996). The existence of the hemangioblast is further supported by the ability of VEGFR-2
positive mesodermal precursors to differentiate into both, angioblastic and hematopoietic lineages in vitro
(Eichman et al., 1997; Choi et al., 1998; Nishikawa et al., 1998).
Cell clusters which bud into the lumen of the aorta to start hematopoiesis do not express the endothelial
specific molecule VEGFR-2 (Jaffredo et al., 1998) and acquire hematopoietic-specific markers
(Vandenbunder et al., 1989; Pardanaud et al., 1996). Hematopoiesis first occurs in the blood islands and
at the period of organogenesis, this potential becomes restricted to the aortic region (Pardanaud and
Dieterlen-Lievre, 1993; Pardanaud et al., 1989; Jaffredo et al., 1998). Primitive erythropoiesis is suggested
to be mediated by an inductive effect of endoderm on associated mesoderm (Pardanaud and Dieterlen-
Lievre, 1993; Pardanaud et al., 1989, 1996). At sites with a dual hematopoietic and endothelial potential,
such as the yolk sac blood islands, floor of the aorta and allantois (Caprioli et al., 1998), studies indicate
that endoderm is in close contact with mesoderm (Kessel and Fabian, 1986; Flamme, 1989). Allantois
vascularizes via vasculogenesis rather than by angiogenesis involving the yolk sac or fetus (See Figure 1
and Downs et al., 1998). Unlike in the chick (Caprioli et al., 1998), vasculogenesis in the mouse allantois is
not associated with erythropoiesis (Downs et al., 1998). Recent experiments report that the transient
contact with endoderm or ectoderm changes the behavior of mesoderm (Pardanaud and Dieterlen-Lievre,
1999). Aorta is formed by distinct endothelial lineages derived from two subpopulations of mesoderm
(Pardanaud et al., 1996). The dorsal mesoderm generates endothelial precursors with only angiopoietic
potential which form the roof and sides of the aorta. The ventral mesoderm or splanchnopleural mesoderm
gives rise to progenitors with a dual hematopoietic and endothelial potential, which make up the floor of the
aorta (Pardanaud et al., 1996).
1.3. Angiogenesis
Vascularization proceeds after the primitive embryonic vasculature is established by the budding of
endothelial cells from pre-existing vessels (See Figure 2). This process called angiogenesis, is
characterized by expansion of the endothelium by proliferation, migration and remodeling. Capillaries are
formed by sprouting or by non-sprouting angiogenesis (Risau, 1997). Angiogenesis is distinct from
vasculogenesis at the cellular level. The molecular mechanisms controlling both processes may overlap
since several genes that are important for angiogenesis are also important for vasculogenesis (Folkman
and D´Amore, 1996; Risau, 1997). Sprouting angiogenesis occurs extra-embryonally in the yolk sac and
intra-embryonally during brain development (See Figure 1). Non-sprouting angiogenesis occurs in the lung
and accounts for splitting of pre-existing vessels by transcapillary pillars. Non-sprouting angiogenesis also
9occurs by the intercalated growth of blood vessels, during which pre-existing capillaries merge, or
additional endothelial cells fuse into existing vessels to increase their diameter and length. This type of
angiogenesis takes place in the heart and during wound healing (Patan et al., 1996; Wilting et al., 1996).
Yolk sac, lung and heart are sites where both sprouting and non-sprouting angiogenesis can occur (Risau,
1997). Angiogenesis is controlled by VEGF and its receptors as well as VEGFR-3 (Carmeliet et al., 1996;
Ferrara et al., 1996; Dumont et al., 1998). Disruption of VEGFR-3 leads to defective large vessel formation
and subsequent cardiovascular failure (Dumont et al., 1998). TGF-β signaling molecule as well as its
receptor are implicated in vasculogenesis and angiogenesis (Dickson et al., 1995; Oshima et al., 1996).
TGF-β signals are mediated by a family of at least nine SMAD proteins, of which SMAD5 plays a role in
yolk sac angiogenesis (Yang et al., 1999; Chang et al., 1999). Ephrin-B2 is a member of the ephrin family
of transmembrane ligands and it marks arteries whereas its receptor Eph-B4 is expressed in veins.
Inactivation of ephrin-B2 gene shows its vital role in angiogenesis preventing the remodeling of veins and
arteries into properly branched structures (Wang et al., 1998). After the primary capillary plexus has
expanded, it becomes remodeled into a mature system via pruning, fusion and regression of pre-existing
vessels with a resulting pattern resembling a tree of arteries, capillaries and veins (Risau, 1997; Carmeliet
and Collen, 1999). During maturation the vasculature becomes surrounded by periendothelial cells, the
pericytes and smooth muscle cells. These cells need to sprout in concert with endothelial cells and this is
mediated by platelet-derived growth factor (PDGF)-B (Lindahl et al., 1998), Tie-2 and angiopoietin-1 (Ang-
1) (Carmeliet and Collen, 1999). Recruited periendothelial cells differentiate and provide structural strength
to the developing vasculature by deposition of the extracellular matrix (ECM) (Carmeliet and Collen, 1999).
Angiogenesis is a dynamic multistep process, which involves retraction of pericytes from the abluminal
surface of the capillary, release of proteases from the activated endothelial cells, degradation of the ECM
surrounding the pre-existing vessels, endothelial cell migration toward an angiogenic stimulus and their
proliferation, formation of tube-like structures, fusion of the formed vessels and initiation of blood flow
(Bicknell, 1997). Unlike vasculogenesis, angiogenesis also occurs during adult life, in the female
reproductive system, wound healing, tissue repair and in many pathological conditions. Angiogenesis
depends on the adhesion receptor integrin αvβ3, allowing endothelial cells to interact with a variety of
extracellular matrix components and leading them to migrate (Leavesley et al., 1993; Brooks et al., 1994;
Cheresh et al., 1991). Besides being the most important survival system for nascent vessels by regulating
cell adhesion to matrix, αvβ3 participates in the full activation of VEGFR-2 triggered by VEGF (Soldi et al.,
1999). Cellular invasion depends on cooperation between adhesion as well as proteolytic modification of
the ECM. Evidence suggests that the matrix metalloproteinase (MMP-2) is localized in a proteolytically
active form on the surface of invasive cells, based on its ability to bind directly αvβ3 (Brooks et al., 1996).
Vascular endothelial VE-cadherin, mediates adhesion between endothelial cells, and participates in their
organization to vessel-like structures (Vittet et al., 1997). Vascular defects appear in VE-cadherin negative
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endothelium when the primitive vascular network expands via sprouting angiogenesis but not during
vasculogenesis (Vittet et al., 1997). Deficiency or truncation of VE-cadherin blocks the capacity of
endothelial cells to respond to survival signals induced by VEGF (Carmeliet et al., 1999).
Fig. 2. Different phases of embryonic vascular development. Endothelial precursors (angioblasts)
differentiate to early endothelial cells (phase 1), which become assembled into a primitive capillary plexus
(vasculogenesis) (phase 2). This emerging network expands via intussusceptive growth, intercalated
growth and sprouting (angiogenesis) (phase 3), after which it becomes remodelled via pruning, fusion and
regression of pre-existing vessels into a tree of arteries, capillaries and veins (phase 4). Endothelial cells
further differentiate and acquire specific properties such as the formation of a tight barrier in the brain, or
the formation of fenestrations in exocrine glands. Adapted from Carmeliet and Collen (1999).
1.3.a. Angiogenic stimulators
Angiogenesis is a complex series of interdependent events, controlled by many different factors. The
angiogenic process results from a shift in the balance of positive and negative mediators, cytokines and
growth factors being the primary inducers (Hanahan and Folkman, 1996). A variety of direct positive
regulators of angiogenesis are identified and some of them are mentioned in the following text. Besides,
there are factors which indirectly induce angiogenesis for example by the mobilization of macrophages,
that could release growth factors (Baird et al., 1985), or chemotactic factors for vascular endothelial cells
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(Banda et al., 1982) or both. Indirect angiogenic factors may also direct the release of stored angiogenic
factors from the ECM or the basement membrane (BM) (Folkman and Klagsbrun, 1987).
The ECM plays an important role in inducing an angiogenic response. BMs and ECMs are the substrates
upon which cells migrate, proliferate and differentiate in vivo. Heparan sulfate proteoglycans (HSPGs) are
very important for the binding of growth factors and enzymes that need to be immobilized and stored in the
ECM for combined action with BM macromolecules like collagen IV, laminin, nidogen/entactin, and
proteoglycans during cellular responses to the ECM (Roberts et al., 1988; Ruoslahti and Yamaguchi, 1991;
Vlodavsky et al., 1993; Wight et al., 1992). Heparan sulphate (HS) also contributes to the integrity and
assembly of the ECM by binding to its fibrillar interstitial collagens, fibronectin, laminin, thrombospondin,
and tenascin as well as to different attachment sites on plasma membranes. HSPGs are also components
of blood vessels (Jackson et al., 1991), supporting proliferating and migrating endothelial cells as well as
stabilizing the capillary wall.
One class of angiogenic factors includes polypeptides like acidic fibroblast growth factor (aFGF) and basic
fibroblast growth factor (bFGF). Both, aFGF and bFGF act as direct angiogenesis factors, expressed by
many tumors in vivo and tumor cell lines in vitro (Christofori, 1997). Low levels of bFGF are detected in the
conditioned medium of endothelial cells (Schweigerer et al., 1987; Sato and Rifkin, 1988) and some tumor
cell lines (New and Yeoman, 1992; Yamada et al., 1992; Sato et al., 1989). These two factors have served
for a long time as the prototype angiogenic factors, being in vitro mitogenic and chemotactic for endothelial
cells and inducing capillary endothelial cells to migrate into three-dimensional collagen matrices to form
capillary-like tubes (Burgess and Maciag, 1989; Basilico and Moscatelli, 1992). Both factors induce
angiogenesis in vivo in the chick chorioallantoic membrane (CAM) and cornea bioassays (Christofori,
1997). FGFs stimulate endothelial cells to secrete collagenase and plasminogen activator proteases able
to degrade BM (Christofori, 1997). Binding of FGFs to the high affinity FGFRs is facilitated by their binding
to heparin or heparin-like molecules which then present FGFs to their high affinity receptors (Yayon et al.,
1991). FGF is sequestered in the ECM, BM, or on the cell surface upon binding to the heparan sulphate
side chains of low-affinity, but high-capacity receptors (Klagsbrun, 1990; D´Amore, 1990). Heparin
enhances the mitogenic action of bFGF (Mansukhani et al., 1992) and protects aFGF and bFGF from
degradation by heat, acid and proteases (Gospodarowicz and Cheng, 1986; Lobb, 1988; Rosengart et al.,
1988). bFGF can be mobilized in a biologically active form from the ECM and BM by displacement with
heparin or by degradation with heparanases and proteinases (Folkman et al., 1988; Saksela et al., 1988;
Vlodavsky et al., 1987). The role of bFGF in vivo was determined by generation of bFGF knockout mice.
These mice are viable, fertile and phenotypically indistinguishable from the normal littermates. However,
the mice display abnormalities in cortical neurogenesis with reduction in neuronal density and have
delayed wound healing (Ortega et al., 1998).
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Another potent endothelial cell mitogen and angiogenesis inducer is VEGF and it is devoid of consistent
and appreciable mitogenic activity for other cell types (Leung et al., 1989; Tisher et al., 1991). VEGF
promotes angiogenesis in  threedimensional in vitro models, inducing microvascular endothelial cells to
invade collagen gels and form capillary-like structures (Pepper et al., 1992). Studies provide evidence for a
potent synergism between VEGF and bFGF in the induction of this effect (Pepper et al., 1992). VEGF
induces sprouting from rat aortic rings embedded in collagen gel (Nicosia et al., 1994). Furthermore, VEGF
elicits a strong angiogenic response in a variety of in vivo models including the CAM (Leung et al., 1989;
Plouet et al., 1989) the rabbit cornea (Phillips et al., 1995), the primate iris (Tolentino et al., 1996), and the
rabbit bone (Connolly et al., 1989). Over the last few years, several members of the VEGF gene family
were identified, including placenta growth factor (PlGF) (Maglione et al., 1991), VEGF-B (Olofsson et al.,
1996a), VEGF-C (Joukov et al., 1996; Lee et al., 1996), VEGF-D (Orlandini et al., 1996; Yamada et al.,
1997; Achen et al., 1998;) and VEGF-E (Lyttle et al., 1994; Ogawa et al., 1998; Meyer et al., 1999). Three
alternative splice isoforms are identified for PlGF, from which the large isoform PlGF-2, differs from the
other two PlGF forms by the insertion of a highly basic 21-amino acid stretch at the carboxyl-end of the
protein (Hauser and Weich, 1993). PlGF-1 induces neovascularization in the rabbit cornea and the CAM
assay either as homodimers or as heterodimers with VEGF165 (Ziche et al., 1997; Oh et al., 1998). PlGF-1
induces proliferation and chemotaxis of human umbilical vein endothelial cells (HUVEC) and capillary
venule endothelial cells (CVEC) (Ziche et al., 1997). PlGF-2 stimulates mitogenesis of HUVEC (Sawano et
al., 1996). VEGF-B stimulates endothelial cell proliferation of HUVE and bovine capillary endothelial (BCE)
cells, in one experimental setting but the results are not reproduced in additional trials with pure
recombinant factors (Olofsson et al., 1996a). VEGF-C stimulates migration and mitogenesis of cultured
endothelial cells (Joukov et al., 1996; Lee et al., 1996; Joukov et al., 1997; Cao et al., 1998). In vivo,
VEGF-C induces lymphangiogenesis in the differentiated CAM (Oh et al., 1998), whereas it stimulates
angiogenesis in the early CAM (Cao et al., 1998). In addition, VEGF-C promotes angiogenesis in the
mouse cornea and in a setting of ischemic hindlimb in rabbits (Cao et al., 1998; Witzenbichler et al., 1998).
VEGF-D is mitogenic for microvascular endothelial and bovine aortic endothelial cells (BAEs) (Achen et al.,
1998; Orlandini et al., 1996). In addition, treatment with VEGF-D induces the formation of an extensive
network of capillary-like cords in a three-dimensional matrix (Marconcini et al., 1999). VEGF-D is an
angiogenic factor in rabbit cornea in vivo in a dose-dependent manner (Marconcini et al., 1999). VEGF-E
stimulates endothelial cell mitogenesis and migration in vitro (Meyer et al., 1999). VEGF-E induces
angiogenesis in vivo, in the rabbit cornea (Meyer et al., 1999), and when injected subcutaneously in
matrigel (Ogawa et al., 1998).
Transforming growth factor-alpha (TGF-α) is an angiogenic factor released by tumor associated
macrophages (Madtes et al., 1988; Rappolee et al., 1988) and many tumor cells (Todaro et al., 1985).
TGF-α is structurally and functionally related to epidermal growth factor (EGF) released by macrophages
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and both induce endothelial cell DNA synthesis in vitro (Schreiber et al., 1986). TGF-α also stimulates
capillary-like tube formation in collagen gels (Sato et al., 1993). The ability of TGF-α  to promote tube
formation is dependent on the release by endothelial cells of substances like tissue-type plasminogen
activator (tPA) and FGF (Sato et al., 1993). In vivo, TGF-α   is more potent than EGF in promoting
angiogenesis in the hamster cheek pouch bioassay (Schreiber et al., 1986). In addition, TGF-α  and EGF
are potent promoters of neoplastic cell growth in many carcinomas (Bicknell et al., 1991).
TGF-β which is not structurally related to TGF-α is synthesized by many normal and tumor cells (Anzano,
1982; Derynck, 1985). TGF-β stimulates neovascularization in vivo when subcutaneously injected to mice
(Roberts et al., 1986). However, several studies utilizing two-dimensional culture conditions find
microvascular endothelial cell proliferation to be inhibited by TGF-β1, TGF-β2 and TGF-β3 raising doubt
as to whether TGF-β functions as an angiogenic factor. It is possible that TGF-β promotes angiogenesis
by differentiating endothelial cells, or stimulates angiogenesis indirectly (Pertovaara et al., 1994; Mervin et
al., 1991; Merwin et al., 1991). Studies also show that low concentrations of TGF-β1 enhance endothelial
cell proliferation (Myoken et al., 1990) and in vitro angiogenesis (Pepper et al., 1993), and high
concentrations inhibit proliferation and angiogenesis.
TNF-α is a cytokine secreted by macrophages at sites of inflammation and is toxic to tumor cells (Pusztai
et al., 1994). TNF-α acts on endothelial cells to exert a procoagulant effect (Fajardo, 1989; van der Poll et
al., 1990). TNF-α inhibits proliferation and antagonizes the mitogenic effect of bFGF in HUVE cells (Frater-
Schroder et al., 1987). TNF-α  also inhibits the proliferation of cultured capillary endothelial cells
(Schweigerer et al., 1987). However, TNF-α does not inhibit mitogenesis of dermal and lung microvascular
endothelial cells (Detman et al., 1990; Meyrick et al., 1991). These differences may be due to the different
concentrations of cytokines used, or to the difference in the sensitivity of endothelial cells originating from
distinct locations. Other in vitro and in vivo studies reveal that TNF-α stimulates angiogenesis at low
doses, whereas it inhibits angiogenesis at high doses (Fajardo et al, 1992). In tissues in vivo the
concentration of TNF-α    is low so that the overall effect of TNF-α  is stimulatory to angiogenesis
(Klagsbrun and D´Amore, 1991). Additional reports show that TNF-α stimulates endothelial cell migration
and tube formation, but inhibits proliferation of these cells. TNF-α stimulates angiogenesis in the rabbit
cornea and in the CAM (Leibovich et al., 1987; Frater-Schroder et al., 1987). Hypoxia induces in vitro the
release of TNF-α by macrophages (Scannell et al., 1993).
Granulocyte-colony stimulating factor (G-CSF) and granulocyte/macrophage-colony stimulating factor (GM-
CSF) are myeloid growth factors required for the survival, growth, and differentiation of hemopoietic
precursor cells. Both are produced in many different tumor types (Bottazzi et al., 1985; Fu et al., 1992) and
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are chemotactic for macrophages in vitro (Wu et al, 1993; Pyke et al., 1991). Recombinant G-CSF and
GM-CSF stimulate the migration and proliferation of human endothelial cells (Bussolino et al., 1989).
Insulin-like growth factor I (IGF-I) is secreted by activated macrophages and it is suggested to have a role
in inflammatory angiogenesis  (Filkins, 1980; Rom et al., 1988). IGF-I induces endothelial cell mitogenesis,
migration and tube formation (Nakao et al., 1992). Interleukin-8 (IL-8) is produced by activated
macrophages (Koch et al., 1992; Yoshimura et al., 1987) and is mitogenic in vitro and stimulates
angiogenesis in the rat corneal assay (Hu et al., 1993; Strieter et al., 1992). Hepatocyte growth
factor/scatter factor (HGF/SF) is a mesenchyme-derived cytokine that stimulates motility and invasiveness
of epithelial and cancer cells. HGF/SF is a potent angiogenic molecule in vivo and its angiogenic activity is
mediated primarily through direct actions on vascular endothelial cells. These include stimulation of cell
migration, proliferation, protease production, invasion, and organization into capillary-like tubes (Rosen et
al., 1997). Nonpeptide substances like prostaglandins PGE1 and PGE2, stimulate microvascular
endothelial cell proliferation and angiogenesis in vivo (Fajardo et al., 1992). The soluble adhesion
molecules E-selectin and VCAM which are involved in inflammatory diapedesis, also induce angiogenesis
in vivo in the rabbit cornea (Gasparini, 1994). Additionally E-selectin and VCAM are chemotactic for
HUVEC in a Boyden chamber assay (Gasparini, 1994). In the same studies antibodies to the known
ligands of E-selectin and VCAM, block HUVEC cell migration.
The angiopoietins have recently joined the members of the VEGF family as the only known growth factors
largely specific for the vascular endothelium. Ang-1  is an angiogenic factor that signals through the
endothelial cell-specific Tie-2 receptor receptor tyrosine kinase (Davis et al., 1996). Ang-1 is essential for
normal vascular development in the mouse. An Ang-1 relative, termed angiopoietin-2 (Ang-2), acts as a
naturally occurring antagonist for Ang-1 and Tie-2 (Maisonpierre et al., 1997). Ang-1 has a role during later
stages of vascular development. Coming into play after VEGF, it enhances vessel branching and
remodeling and promotes maturation and stabilization of vessels (Gale and Yancopoulos, 1999). Ang-1 is
potent in inducing sprouting angiogenesis of adrenal-cortex–derived microvascular endothelial cells in vitro
in three-dimensional fibrin gels and it is only a weak mitogen for HUVEC (Koblizek et al., 1998). Instead,
Ang-2 must act as a destabilizing protein being expressed at sites of vascular remodeling leading to vessel
regression in the absence of VEGF or causing vessel outgrowth in the presence of VEGF (Maisonpierre et
al., 1997).
Heparin was first found to induce endothelial cell migration and proliferation in vitro (Fraser et al., 1983),
but it was then shown that it is not angiogenic in vivo by itself but potentiates the angiogenic activity of
tumor cell extracts (Damon et al, 1989). Species of heparin and HS promote dimerization and receptor
binding of bFGF (Yayon et al., 1991; Ornitz et al., 1992), as well as bFGF-mediated mitogenesis (Ornitz et
15
al., 1992),  suggesting that bFGF-HSPG complexes serve as the biological active form of this growth
factor. Cell surface heparin-like molecules are also involved in binding of VEGF to its high affinity receptor
sites (Gitay-Goren et al., 1992). Released FGF can be sequestered from its site of action by binding to HS
in the ECM (Vlodavsky et al., 1991; Bashkin et al., 1989) and saved for emergencies, such as wound
repair and neovascularization (Vlodavsky et al., 1993).
ANGIOGENIC ASSAYSINDUCER
IN VITRO IN VIVO
aFGF 1, 2, 3 7, 8
bFGF 1, 2, 3 7, 8
VEGF 1, 2, 3, 5 6, 7, 8
PlGF PlGF-1: 1, 2 PlGF-2: 1 PlGF-1: 7, 8
VEGF-B VEGF-B167: (1)
VEGF-C ∆N∆C: 1, 2, 3  wt: 2 ∆N∆C: 7, 8
VEGF-D ∆N∆C: 1, 2, 3 ∆N∆C: 8
VEGF-E VEGF-ED1701: 1, 2, 3
VEGF-ENZ7: 1 VEGF-ENZ2: 1
VEGF-ED1701: 8
VEGF-ENZ7: 10
IGF-1 1, 2, 3, 5
Ang-1 (1), 4
TGF-α (In) 1, 2, 3 11
TGF-β (In) 10
ANGIOGENIC ASSAYSINDUCER
IN VITRO IN VIVO
PGEs (In) 1
GM-CSF 1, 2
G-CSF 1, 2
Soluble E-selectin 2 8
Soluble VCAM 2 8
EGF 1 11
TNF-α (In) 2, 3 7, 8
IL-8 1 8
SF 1, 2, 3
Abbreviations: (In): indirect angiogenic factor, ∆N∆C: mature form of VEGF-C or VEGF-D.
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In vitro angiogenic assays are market by numbers: proliferation=1, migration=2, tube formation=3,
sprouting from microcarrier beads in fibrin gel=4, sprouting from rat aortic ring=5. In vivo angiogenic assays
are marked by numbers: rabbit bone= 6, CAM=7, cornea pocket=8, limb ischemia model=9, subcutaneous
matrigel implantation=10, hamster cheek pouch assay=11, rabbit ear lobe=12.
1.3.b. Angiogenic inhibitors
There are a number of peptide growth regulators, which inhibit vascular endothelial cell proliferation. Many
of these peptide growth factors have both stimulatory and inhibitory activity on a single cell, depending on
the context of the other signaling molecules present (Sporn and Roberts, 1988). Thrombospondin, an
extracellular matrix protein, suppresses neovascularization in vivo in the rat cornea (Rastinejad et al.,
1989) and also inhibits endothelial cell proliferation, migration and angiogenesis in vitro (Bagavandoss and
Wilks, 1990; Dawson et al., 1997; Good et al., 1990; Iruela-Arispe et al., 1991; Rastinejad et al., 1989;
Taraboletti et al., 1990; Tolsma et al., 1997; Tolsma et al., 1993; Volpert et al., 1995). Another factor able
to down-regulate or inhibit angiogenesis is INF-α, being potent in regressing hemangiomas (Ezekowitz et
al., 1992), and highly vascular Kaposi´s sarcomas (Real et al., 1986). INF-γ inhibits aFGF-induced
endothelial cell proliferation (Friesel et al., 1987) capillary formation (Tsuruoka et al., 1988) and endothelial
cell growth in vitro (Heyns et al., 1985). INF-γ is implicated as an anti-angiogenic agent in vivo (Orchard et
al., 1989; White et al., 1989). Platelet factor 4 is a strong anti-angiogenic factor in vitro (Taylor and
Folkman, 1982; Walz and Hung, 1985; Jouan et al., 1999), and inhibits growth of solid tumors (Sharpe et
al., 1990). TGF-β1 induces cells to secrete thrombospondin, in this way enhancing its own effects
(Canfield and Schor, 1995; Penttinen et al., 1988). Protamine is an inhibitor of angiogenesis in the embryo,
in tumorigenesis, in inflammation and immune responses (Taylor and Folkman, 1982).
Angiostatin and endostatin inhibit specificly endothelial cell proliferation and are derived from the
proteolytic cleavage of native proteins. Angiostatin an internal fragment of plasminogen produced by
primary tumors, was identified as an endogenous inhibitor of endothelial cell proliferation and inhibits
angiogenesis in vivo. When the primary tumor is present, it in certain cases suppresses metastatic growth
by secreting this circulating angiogenesis inhibitor. After tumor removal, metastases neovascularize and
grow (O´Reilly et al., 1994; Holmgren et al., 1995). Endostatin, a C-terminal fragment of collagen XVII, is
another endogenous inhibitor of angiogenesis. It suppresses endothelial cell proliferation in vitro and in
vivo angiogenesis in the CAM (O´Reilly et al., 1997).
Several other endogenous inhibitors of angiogenesis have been identified, such as an interferon-inducible
protein. It is able to inhibit angiogenesis in vivo, but has no effect on endothelial cell growth, attachment,
and migration in vitro (Angiolillo et al., 1995). Two chemokines, gro-α and gro-β, specifically inhibit growth
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factor stimulated proliferation of capillary endothelial cells and gro-β is potent in inhibiting in vivo blood
vessel formation in CAM (Cao et al., 1995). 16-kDa N-terminal fragment of prolactin is a potent inhibitor of
angiogenesis (Clapp et al., 1993). Steroids administered in combination with heparin inhibit angiogenesis
in the CAM, and in rabbit corneas (Folkman et al., 1983; Nikolic et al., 1986). The nonanticoagulating
derivative of heparin, heparin adipic hydrazide (HAH), covalently linked to the antiangiogenic steroid,
cortisol, has an antiproliferative effect on murine pulmonary capillary endothelial cells (Thorpe et al., 1993).
Collagenase inhibitors inhibit angiogenesis, which may depend on the importance of BM synthesis and
degradation in the formation of new capillaries (Folkman and Ingber, 1992). Other protease inhibitors like
plasminogen activator inhibitor 1 (PAI-2) or 2 (PAI-1), and tissue inhibitors of metalloproteinases (TIMP-1
and TIMP-2) inhibit the degradation of BMs and endothelial cell invasion of the ECM (Fan et al., 1995).
Simultaneous expression of enzyme and inhibitor stimulates neovascularization, while protecting newly
vascularized tissues. Endothelial cells secrete proteolytic enzymes such as plasminogen activator (PA)
enabling them to penetrate the BM and migrate into surrounding tissues (van et al., 1991). Macrophages
secrete enzyme inhibitors and produce cytokines that alter enzyme secretion by endothelial cells.
Recently a fragment of MMP-2, which comprises the C-terminal hemopexin-like domain, termed PEX, was
shown to prevent the binding of this enzyme to αvβ3 and block cell surface collagenolytic activity (Brooks
et al., 1998). PEX blocks MMP-2 activity on the CAM where it disrupts angiogenesis and tumor growth
(Brooks et al., 1998).
INHIBITORS IN ANGIOGENIC ASSAYS
IN VITRO IN VIVO
TNF-α: 1 a-αvβ3: 7
a-αvβ5: 7, 8
TGF-β: 1 PEX: 7
Steroids: 7
Thrombospondin: 1, 2, 3 Thrombospondin: 8
Gro-β: 7
INF-γ: 1, 2, 3 Heparin-cortisone
IFN-α, IFN-γ, IL-1
Angiostatin: 1 Platelet factor 4, TNF-α,   Protamine
Interferon-inducible protein
Endostatin: 1 N-terminal fragment of prolactin
Collagenase inhibitors
Gro-α, -β: 1 PAI-1, -2, TIMP-1, -2
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In vitro angiogenic assays are market by numbers: proliferation=1, migration=2, tube formation=3,
sprouting from microcarrier beads in fibrin gel=4, sprouting from rat aortic ring=5. In vivo angiogenic assays
are marked by numbers: rabbit bone= 6, CAM=7, cornea pocket=8, limb ischemia model=9, subcutaneous
matrigel implantation=10, hamster cheek pouch assay=11, rabbit ear lobe=12.
1.4. Lymphangiogenesis
The lymphatic vessels penetrate most of the tissues as a dense vascular network. Lymphatics control the
microcirculation of tissues, by draining fluid from the interstitial spaces which is then being filtered by lymph
nodes and returned to the systemic circulation through the thoracic and lymphatic ducts and the
lymphaticovenous anastomoses (Leak, 1970). They also take part in the immune functions, inflammation
and tumor metastasis. The lymphatic vascular system is not continuous like the blood vascular system,
being rather a one-way passage channel. The lymphatic vasculature has evolved in response to high
pressure and it bridges the disparity between the intracellular and extracellular environments (Stone and
Hugo, 1972). The mechanism of molecular exchange between plasma and interstitial fluid is based on
diffusion, rather than hydrodynamic flow like for blood vessels (Pappenheimer, 1953).
Lymphangiogenesis has many similarities but also differences with angiogenesis. The principal difference
is that the lymphatic vessels develop much after the formation of veins and arteries. The first lymphatic
plexuses accompany veins but later they also grow along arteries (Wilting et al., 1999). Lymphatic
endothelial cells seem to derive only from venous endothelium, and new lymphatic endothelial cells form
from pre-existing ones (Wilting et al., 1999). The thoracic duct endothelium is able to form new lymphatic-
like capillaries, in collagen gel (Clark and Clark, 1932; Nicosia, 1987). Lymphatic vessels are found
everywhere in the body except in the central nervous system, the bone marrow, the intralobular portion of
the liver, the eye, the internal ear, and the fetal placenta (Bailey, 1964). Similar mechanisms operate in
lymphangiogenesis and angiogenesis, such as sprouting, intussusceptive and intercalated growth, fusion
and finally regression (Wilting et al., 1999). Studies on the lymphatic system have been fragmentary
compared to the blood vascular system. Three theories are presented to explain the origin of lymphatic
vessels.
The first theory suggested by Dr Sabin, proposes formation of primary lymphatic structures from sprouts of
large central veins in certain locations of the body. These sprouts form the primordial lymph sacs by fusion,
which then give rise to the primary lymph nodes. The sinuses of the lymph nodes form by a process
resembling intussusceptive growth. In mammals the lymphatic sacs arise from the anterior cardinal veins in
the neck or from the inferior vena cava and the adjacent veins of the kidney. The primary lymphatic sacs
and the thoracic duct make the primary lymphatic system (Sabin, 1909; Sabin, 1902; Sabin, 1912). Based
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on this theory of centrifugal spread, the primary sacs enlarge and form sprouts into the periphery of the
embryo (Zadvinskis et al., 1992). The lymphatic network seems to further grow by intercalated growth
(Wilting et al., 1999). According to the second, so called centripetal theory, lymphatics develop from
lymphangioblasts in blind mesenchymal spaces that spring up either around degenerating venous
channels or in their vicinity but independently of them. These lymphatic spaces spread from the periphery
of the embryo by annexing with other similar spaces and establishing anastomoses with the venous
system (Kampmeier, 1960). The third theory combines the two previous theories and supports the venous-
mesenchymal origin, suggesting that lymphatics arise from the confluence of small venules and from
mesenchymal aggregates (Kutsuna, 1933; van der Jagt, 1932). The fact that the lymph plexuses are
located adjacent to veins and are connected to them (Sabin, 1909; van der Putte, 1975), supports the
venous origin of the lymphatics. Since lymphatics also develop late in embryogenesis the theory of
mesenchymal origin appears less favorable (Wilting et al., 1999).
1.5. Heterogeneity of endothelial cells
Endothelial cells lining the blood and lymphatic vessels display unique phenotypes according to the
specific functions that they perform. The various regions of the vascular plexus have different intercellular
junctions that regulate vascular permeability, leukocyte extravasation and vascular proliferation. Different
molecules at junctions are not only important for maintaining adhesion but can also play a role in cell-to-
cell signal transduction. On the basis of morphological and functional characteristics at least three types of
junctions are described in endothelial cells. Large arteries have a high frequency of tight junctions, which
form a very close contact between adjacent cells. In the endothelium of postcapillary venules tight
junctions are virtually absent (Dejana et al., 1995). Gap junctions are clusters of transmembrane
hydrophilic channels that allow direct exchange of ions and small molecules between adjacent cells
(Dejana et al., 1995). Cell-to-cell adherens junctions are cellular membrane contacts formed by cadherins
as transmembrane glycoproteins that mediate the physical attachment between cell membrane and an
intracellular undercoat network of cytoplasmic proteins and actin microfilaments (Dejana et al., 1995).
Endothelial cell junctions can be modulated in the angiogenic process, possibly by vascular growth factors
or inflammatory cytokines affecting the expression or phosphorylation state of the junctional proteins
(Dejana et al., 1995). During the formation of vascular sprouts endothelial cells need to detach and invade
the surrounding tissues, which is accomplished by the interruption of junctions. VEGF also acts as a
permeability factor for the vasculature, possibly decreasing the endothelial junction strength (Connolly et
al., 1989).
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Morphological criteria divide the microvascular endothelium to continuous, fenestrated and discontinuous,
correlating with vascular permeability properties (Bennet et al., 1959; Majno, 1965). Continuous
endothelium forms the blood-brain barrier, with “tight” junctions between the capillary endothelial cells that
allow only very small molecules to pass into the brain. Discontinuous endothelium is found in the liver,
where the clefts between the capillary endothelial cells are wide open, so that almost all dissolved
substances of the plasma, including the plasma proteins, pass from the blood into the liver tissues.
Fenestrated endothelium is located to the glomerular tufts of the kidney, in which numerous small oval
windows called fenestrae penetrate directly through the middle of the endothelial cells, so that tremendous
amounts of substances can be filtered through the glomeruli without having to pass through the clefts
between the endothelial cells (Risau, 1995).
There are also differences between the endothelia of large vessels and the microvasculature. The
endothelium of large vessels regulates vascular tone and blood pressure and the microvasculature is
involved in neovascularization participating as well in the exchange of oxygen and nutrients (Kumar et al.,
1987). The endocardium, which is a specialized type of large vessel endothelium, is the first endothelium
to be formed. It differentiates from a more axial mesoderm, and is the only endothelium to trans-
differentiate to mesenchyme during the formation of the endocardial cushion tissue (Sinning et al., 1922).
The lymphatic endothelium differs from the blood vascular endothelium in many morphological aspects.
Lymphatics have an irregular and wide lumen, and an attenuated endothelial wall. Except for the collecting
lymphatic capillaries lymphatics do not develop a continuous BM (Casley-Smith, 1980; Oh et al., 1997).
Lymphatic vessels lack laminin and type IV collagen (Barsky et al., 1983; Ezaki et al., 1990). Their
endothelial cells lack tight junctions and they posses anchoring filaments attaching them to the surrounding
connective tissue (Leak, 1970). Because of their permeability and their poorly developed BM, lymphatics
have been proposed as the main routes for tumor metastasis (Cann et al., 1995).
Altered endothelial permeability and organization of the vasculature is associated with hemangiomas,
atherosclerosis and inflammatory diseases (Dejana et al., 1995). Abnormal function of the lymphatic
system is implicated in many disease states such as lymphedema, ascites, inflammation, infectious and
immune diseases, fibrosis and tumors such as Kaposi´s sarcoma and lymphangioma/lymphangiomatosis
(Goldberg and Rosen, 1997). In lymphedema, the lymphatic system fails to remove the plasma proteins
passing into the tissues, which causes edema (Casley-Smith, 1984). Lymphangioma is a vascular
malformation containing lymph with a defect in the deep collecting lymphatics (Cotran et al., 1994).
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2. Neovascularization during adult life
Most adult tissues have little ongoing angiogenesis. The endothelial cell proliferation is high during
embryonic and postnatal development, but adult endothelial cell turnover is very low (Risau, 1997). The
endothelium is in a quiescent state during the entire life of a normal adult, yet is able to proliferate in
pathological conditions (Risau, 1995). Angiogenesis taking place in the adult may resemble embryonic
angiogenesis including remodeling of cell adhesions and junctions, induction of proteolytic processes and
neutralization of inhibitors (Risau, 1997). Regression occurs in the capillaries of the primitive vascular
plexus during embryogenesis so that few of them persist until adulthood (Risau, 1995). During adult life,
physiological angiogenesis occurs in the female reproductive cycle including the development of the
ovarian follicle and corpus luteum, and in the endometrium during each menstrual cycle (Hansen-Smith,
1988). Neovascularization plays a major role in processes such as wound healing, tumor growth and
metastasis, rheumatoid arthritis, diabetic proliferative retinopathy, atherosclerosis, psoriasis, and many
others.
2.1. Female reproductive tract angiogenesis
The ovary is one of the adult organs, in which angiogenesis normally occurs during the female
reproductive cycle. The development and endocrine function of the ovarian corpus luteum (CL) are
dependent on the growth of new capillary vessels. Progesterone release by CL is essential for implantation
and maintenance of pregnancy (Bassett et al., 1943). During follicular growth, the theca interna becomes
richly vascularized. Following ovulation, the thecal vessels invade the ruptured follicle and form a
microvascular plexus that nourishes the developing CL (Bassett et al., 1943). Multiple mediators are
involved in CL angiogenesis including VEGF, bFGF (Ferrara et al., 1998; Gospodarowicz et al., 1985),
Ang-1 and Ang-2 (Maisonpierre et al., 1997). VEGF or a related factor is essential for CL angiogenesis,
since treatment with soluble receptor VEGFR-1 extracellular domain results in complete suppression of CL
angiogenesis (Ferrara et al., 1998). At the same time endometrium fails to mature, probably reflecting
suppression of ovarian steroid production and an inhibition of locally produced VEGF (Ferrara et al., 1998).
2.2. Wound healing
Angiogenesis during wound healing is a good example of pathophysiological neovascularization during
adult life, where the capillaries regress after the termination of the process. Angiogenesis is part of the
normal wound repair process, where it provides a supply of nutrients, promotes granulation tissue
formation and clears debris. Neovascularization in wounds depends on cell-cell interactions, cell-ECM
interactions and also the balance between angiogenic agonists and antagonists. Tissue injury is followed
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by exudation of plasma constituents including fibrinogen. Fibrinogen provides the substrate for the
generation of a fibrin-containing matrix, which is subsequently replaced by granulation tissue (Schäfer et
al., 1994). Replacement involves proteolysis by plasmin, which is generated from plasminogen present in
plasma and the interstitial fluid (Miyashita et al., 1988). PAs convert plasminogen into plasmin by limited
proteolysis (Dano et al., 1985). Polymorphonuclear leukocytes (PMNs), monocytes, fibroblasts and
capillary endothelial cells are involved in the organization of the primary wound matrix (Dvorak et al.,
1988). In vitro, these cells express PAs (Bajpai and Baker 1985; Granelli-Piperno et al., 1977; Chapman et
al., 1982; Hekman et al., 1985), surface receptors for urokinase plasminogen activator (uPA) (Blasi et al.,
1986; Bajpai and Baker, 1985; Fibbi et al., 1988) and cell surface binding sites for plasminogen (Miles and
Plow, 1987; Hajjar et al., 1986).
Many in vitro and in vivo studies suggest the involvement of bFGF in the angiogenic activity during wound
healing. bFGF can be sequestered within cells and these stores can be released during cell injury, lysis or
death (Gajdusek and Carbon, 1989; Muthukrishnan et al., 1991). Proteases found in the early wounds are
also able to release bFGF stored in the ECM (Bashkin et al., 1989; Saksela et al., 1990; Villaschi and
Nicosia, 1993). Platelets at the wound site participate in coagulation and release several growth factors
and enzymes. Platelet derived growth factor (PDGF) for example is a powerful chemoattractant for
circulating neutrophils, monocytes and tissue macrophages (Ondrick and Samojla, 1992). By releasing
bFGF and TNF-α, macrophages are able to exert angiogenic activity in the depths of a wound where
oxygen tension is low and lactate is high due to anaerobic metabolism. For example phagocytosis of fibrin
increases macrophage angiogenic activity (Dvorak, 1986; Knighton et al., 1983). During the latter stages of
wound repair, macrophages stimulated by hypoxia, cytokines, or inflammatory mediators, synthesize new
factors like TGF-β and VEGF (Knighton et al., 1983). During the terminal stages of healing the production
of angiogenic factors is decreased when granulation tissue is formed and the area is less hypoxic
(Constant et al., 1996; Hunt et al., 1978).
Hypoxia is known to increase VEGF levels but whether it stimulates wound angiogenesis is an open
question. VEGF, produced by keratinocytes together with other mediators may play a role in wound
angiogenesis (Brown et al., 1992; Frank et al., 1995). VEGF is produced in many in vitro and in vivo
systems under hypoxic conditions, supporting the view of VEGF production in hypoxic wounds (Shweiki et
al., 1992).
2.3. Angiogenesis in retina
In the retina, neovascularization is associated with a number of disease processes, the most common of
which is diabetic retinopathy. Occlusion of retinal vessels leading to retinal ischemia is a feature shared by
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most diseases in which retinal neovascularization occurs. Hypoxia-induced expression of VEGF by retinal
cells is a common factor in these diseases (Pe’er et al., 1995). VEGF is a survival factor for the endothelial
cells in the embryonic retina and hyperoxia inhibits VEGF expression, leading to regression and death of
retinal vessels, which can be rescued by intaocular injection of the factor (Alon et al., 1995). It is not clear,
whether hyperoxia induces blood vessel regression under normal conditions, VEGF is instead critical for
the survival of immature/remodeling vessels. Independence from VEGF is a sign of maturation when
vessels have already acquired a pericyte coating (Benjamin et al., 1998).
2.4. Tumor angiogenesis
Tumors or metastases growing initially as small avascular masses need to gain a blood supply, which
permits them to grow beyond a few millimeters in diameter. Tumors implanted into isolated perfused
organs fail to develop, but when these tumors are implanted into the ocular chambers of mice they grow.
Tumors in the second case obtain oxygen and nutrients from the organism, by establishing a blood supply
necessary for their growth (Folkman et al., 1963; Gimbrone et al., 1973; Gimbrone et al., 1972). The
induction of angiogenesis is mediated by many angiogenic molecules released by tumors and host cells
(Ellis and Fidler, 1995). Activation of endothelial cell proliferation and migration can be achieved by
reduction of inhibitor levels or increase of activators (Hanahan and Folkman, 1996).
The most widely accepted theory of initial avascular growth of tumors and metastases may not be valid in
all the settings. Avascular growth occurs in tumors that arise in epithelial structures that are separated from
the underlying vasculature. However, tumors that arise within or metastasize to vascularized tissue, coopt
existing blood vessels. This coopted host vasculature does not immediately undergo angiogenesis to
support the tumor but instead regresses, leading to a secondarily avascular tumor and massive tumor cell
loss. Finally, the remaining tumor is rescued by angiogenesis at the tumor margin (Holash et al., 1999).
The angiogenic antagonist Ang-2 and pro-angiogenic VEGF may be critical regulators of the balance
between vascular regression and growth. This is supported by the increased expression of Ang-2 in the
endothelium of coopted tumor vessels and induced VEGF expression in the hypoxic tumor periphery
(Maisonpierre et al., 1999). Thus, the angiogenic properties of tumor-derived VEGF may be facilitated
when vessels are destabilized by Ang-2 (Holash et al., 1999). In established human tumors because of
ongoing angiogenesis and remodeling of tumor vessels, there is a significant fraction of vessels that have
not yet recruited periendothelial cells. The dependence of these immature vessels on vascular survival
factors leads to their regression following VEGF withdrawal (Benjamin et al., 1999). Yet, very recent
findings describe a new mechanism by which some aggressive tumors may acquire a blood supply.
According to these findings which still need to be verified tumor cells metamorphose into vessels that
either carry blood or connect to the host´s blood supply (Bissell, 1999). The generation of patterned
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vascular channels by deregulated aggressive tumor cells is observed in human melanomas in which the
establishment of a microcirculation also facilitates metastasis (Maniotis et al., 1999).
Tumors have a complex morphology, differing in regional vasculature, host infiltrates, and connective
tissue components (Callahan and Campbell, 1989; Heppner, 1984). Tumor vessels are anatomically
heterogeneous structures, being relatively immature. They are lined by a simple endothelium, and have
fewer pericytes and smooth muscle cells compared to normal tissue vessels. Tumor vessels are also more
permeable to circulating plasma proteins and have differing capacities to leak macromolecules depending
on their location (Dvorak et al., 1988).
Neovascularization takes place following different pathways, where tumor cells either synthesize their own
angiogenic factors (Klagsbrun et al., 1986), or attract macrophages which release them (Polverini and
Leibovich, 1984). Tumors secrete collagenases and heparanases (Kramer et al., 1982) and degrade the
ECM, which subsequently releases stored angiogenic factors (Folkman and Klagsbrun, 1987). Tumor cells
at the same time are able to release several angiogenic factors like VEGFs (Senger et al., 1983).
Hypoxia-induced VEGF (Shweiki et al., 1995) contributes to the onset of tumor-associated angiogenesis
(See Figure 3). In tumors with a significant component of necrosis such as glioblastoma multiforme, VEGF
mRNA expression is not uniform but occurs primarily in clusters of tumor cells at the border between viable
tumor and necrotic areas (Plate et al., 1992). This localization is consistent with local hypoxia being a
major inducer of VEGF gene expression (Shweiki et al., 1992). VEGF seems to play an essential role in
tumor and wound angiogenesis, partly by inducing permeability with resulting plasma protein leakage from
postcapillary venules. Subsequently, clotting of extravasated fibrinogen results in the formation of a fibrin
gel substratum, ideal for endothelial and tumor cell growth (Dvorak, 1986; Dvorak et al., 1987).
Antagonists of VEGF inhibit the growth of many tumors. Antibodies against VEGF have a potent inhibitory
effect on the growth of three human tumor cell lines injected subcutaneously in nude mice (Kim et al.,
1993). In a nude mouse model of liver metastasis VEGF antibodies inhibit human colon carcinoma cell
growth thus decreasing the number of metastases (Warren et al., 1995). Retrovirus-mediated expression
of a dominant negative VEGFR-2 mutant suppresses the growth of glioblastoma multiforme as well as
other tumor cell lines in vivo (Millauer et al., 1994; Millauer et al., 1996). In an in vivo model of
teratocarcinomas VEGF null ES cells were impaired in their ability to form tumors in nude mice (Hillberg et
al., 1992).
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Fig. 3. The figure depicts schematically the generation of a new capillary sprout from a pre-existing vessel
towards the hypoxic region of a tumor, such as a postcapillary venule (on the left). Numbers refer to
various, often overlapping stages of the process. Angiogenic factors secreted by the tumor cells activate
the vascular endothelium lining the vessel and pericytes (white) retract (1). Proteases degrade the
basement membrane beneath endothelial cells (2), which subsequently become less adherent (3). The
αvβ3 and αvβ5 integrins are important at these stages (Brooks et al., 1994; Brooks et al., 1994;
Friedlander et al., 1995). Vascular permeability is also increased, allowing fibrin deposition into the tissue
(4). Endothelial cells migrate toward the angiogenic stimulus (5) and enter the cell cycle (6). Circulating
endothelial precursors may also become incorporated to the growing vessel sprout (7). New vessels
mature and become established when periendothelial structures are formed (8), but this process is often
defective in tumors. Abundant VEGF is secreted by hypoxic regions of the tumor (shown dark). VEGF is
involved in most of the steps shown, while Ang-1 may function in concert with VEGF to stimulate vessel
sprout invasion. Ang-2, which becomes upregulated in endothelial cells of angiogenic capillary sprouts may
disrupt the interactions between endothelial cells and pericytes, thus sensitizing the endothelium to the
mitogenic and chemotactic signals secreted by the tumor. Adapted from Veikkola and Alitalo, 1999.
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2.5. Tumor lymphangiogenesis
The role played by the lymphatic vascular system in tumorigenesis has gained relatively little attention,
despite the potential clinical relevance of lymphangiogenesis. The presence of lymphatic vessels in solid
tumors is a matter of debate. According to one report, breast cancers posses lymphatic-like labyrinths (Van
Netten et al., 1996). Intra-tumoral lymphatics are identified by others in cancers, but it is not clear whether
these lymphatics are residual, newly formed, obstructed, malformed, or labyrinthine (Reichert, 1926; Witte
et al., 1997). Tumor microvessels resemble lymphatics more than typical blood vessels, suggesting an
indeterminate mix of embryonic vessels in the growing tumor (Witte and Witte, 1997). Furthermore, it has
been argued that lymphangiogenesis does not take place in normal adult life or in tumors (Folkman, 1996).
Due to the high interstitial pressure in the tumors, generated by leaky blood vessels and rapidly dividing
tumor cells, it is thought that the lymphatic vessels collapse (Jain, 1997), or are compressed not having the
possibility to extend into most solid tumors (Baish et al., 1997). Due to the lack of functional lymphatics in
tumors, the peritumoral host lymphatics in this case drain the fluid and macromolecules coming from the
tumors (Baxter and Jain, 1990).
3. Receptor tyrosine kinases
Key signals regulating developmental cell growth and differentiation, as well as remodeling and
regeneration of adult tissues, are mediated by polypeptide growth factors and their transmembrane
receptors, many of which are tyrosine kinases (RTKs) (Mustonen and Alitalo, 1995; van der Geer et al.,
1994). Several families of receptor tyrosine kinases are characterized and some of them are strictly
endothelial cell-specific.
Growth factor receptors with protein tyrosine kinase activity have a similar molecular topology. Firstly, they
consist of a large glycosylated extracellular domain defining the receptor binding characteristics. Secondly,
they consist of the hydrophobic transmembrane region anchoring the receptor in the plane of the plasma
membrane. Thirdly, they contain the juxtamembrane domain involved in modulation of receptor functions
by e.g protein phosphorylation. Fourthly, they contain the protein tyrosine kinase domain, which is the
catalytic domain of the receptor, indispensable for signal transduction and induction of cellular responses.
The kinase domain of subclass III RTKs is divided into two halves by insertions of hydrophilic amino acid
residues. The role of this kinase insert region is to modulate receptor interactions with certain cellular
substrates. Lastly, they contain the carboxy-terminal tail which interacts with the substrate binding sites of
the protein tyrosine kinase region, modulating the capacity of the tyrosine kinase (TK) region to interact
with exogenous substrates (Ullrich and Schlessinger, 1990).
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RTKs are activated by polypeptide ligands commonly known as growth factors or cytokines. Signaling
involves ligand binding, which induces a conformational change in the external domain of the receptor
resulting in its dimerization (Ullrich and Schlessinger, 1990). This event results in receptor trans-
phosphorylation at specific tyrosine residues and activation of the catalytic domains for the phosphorylation
of cytoplasmic substrates. These phosphorylated tyrosine residues may serve to control the kinase activity
of the receptor, and to create docking sites for the cytoplasmic signaling molecules, which are often
substrates for the kinase. These molecules are adapters or enzymes themselves, linking RTKs to different
signaling pathways. The interaction of these proteins with the activated RTKs can initiate signaling
pathways leading to the nucleus or other cellular targets (Heldin, 1995). Following ligand binding and
dimerization, receptors are internalized for degradation or recycling in order to attenuate signaling (Cadena
and Gill, 1992).
3.1. Receptors for the VEGF family of growth factors
There are two subfamilies of receptor tyrosine kinases, which are specific to the vascular endothelium, the
VEGFR subfamily and the Tie receptor subfamily. To date, three VEGFRs which are members of the class
III RTKs are known, VEGFR-1, VEGFR-2 and VEGFR-3 (Shibuya et al., 1990;  Terman et al., 1991;
Aprelikova et al., 1992). The other members of the class III receptor family are the receptors for PDGF,
colony stimulating factor-1 (CSF-1R/c-fms), stem cell factor (SCFR/c-kit) and the FLT3/FLK2 receptor
(Claesson-Welsh et al., 1989; Matsui et al., 1989; Matthews et al., 1991; Rosnet et al., 1991; Sherr, 1990;
Witte, 1990). The VEGFRs have seven immunoglobulin homology domains (Ig) whereas the prototype of
this subfamily PDGF receptor, has only five Ig repeats, as do CSF-IR, C-KIT and Flt3. Based on this
structural similarity, the VEGFRs comprise a separate subfamily. For VEGFRs the second immunoglobulin
homology domain is critical for ligand binding, whereas the three first domains are necessary to establish
full affinity (Barleon et al., 1997; Davis-Smyth et al., 1996; Davis-Smyth et al., 1998; Wiesmann et al.,
1997). Neuropilin (NP-1) is a non tyrosine kinase receptor shown recently to bind VEGF165 (Soker et al.,
1996; Soker et al., 1998). NP-1 binds also PlGF-2, VEGF-B and VEGF-ENZ2but not PlGF-1 (Migdal at al.,
1998; Makinen et al., 1999; Wise et al., 1999).
28
Fig. 4. Schematic view of the receptors for the VEGF family of growth factors and interaction of VEGFs
with the various receptors.
Growth factors or
receptors
Isoforms Heparin
binding
Receptors
VEGF VEGF121, VEGF165, VEGF189,
VEGF206, VEGF-145
VEGF165, VEGF189,
VEGF206
VEGFR-1, VEGFR-2
NP-1 (VEGF165)
PlGF PlGF-1, PlGF-2, PlGF-3 PlGF-2, VEGFR-1
NP-1 (PlGF-2)
VEGF-B VEGF-B167,
VEGF-B186
VEGF-B167 VEGFR-1
NP-1 (VEGF-B167, VEGF-B186
fully processed)
VEGF-C VEGFR-2, VEGFR-3
VEGF-D VEGFR-2, VEGFR-3
VEGF-ENZ2,
VEGF-ENZ7
VEGF-ED1701
VEGFR-2,
NP-1 (VEGF-ENZ2)
VEGFR-1/FLT-1 VEGFR-1
Soluble VEGFR-1
VEGFR-1
Soluble VEGFR-1
VEGFR-2/KDR VEGFR-2 VEGFR-2
VEGFR-3/FLT4 VEGFR-3 long
VEGFR-3 short
Neuropilin-1 HSPG sVEGFR-1 VEGFR-1 VEGFR-2 VEGFR-3
PlGF VEGF-B VEGF VEGF-C VEGF-D VEGF-E
S-S
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3.1.a. VEGFR-1
Structure and chromosomal localization
VEGFR-1 originally isolated from a human placental cDNA library, is designated flt (fms–like tyrosine
kinase), due to its close structural relationship to members of the fms family of receptor tyrosine kinases
(Shibuya et al., 1990). Mouse and rat homologues of human VEGFR-1 were also cloned (Choi et al., 1994;
Finnerty et al., 1993; Yamane et al., 1994). The human gene is located on chromosome 13q12-13
(Shibuya et al., 1990), and its mouse homologue on chromosome 5 (Rosnet et al., 1993). The promoter
region contains a TATA box, a GC-rich region, putative transcription factor binding elements such as a
cAMP response element binding the transcription factor (CREB/ATF) and also an ETS binding site
(Morishita et al., 1995). VEGFR-1 promoter contains sequences matching the hypoxia inducible factor-1α
consensus binding site (Gerber et al., 1997; Ikeda et al., 1996).
VEGFR-1 is a 180 kDa transmembrane glycoprotein, its mRNA occurs mainly as a 7.5-8.0 kb transcript,
and alternative splicing produces a shorter soluble protein. The soluble form of VEGFR-1 encodes six of
the N-terminal extracellular ligand-binding Ig domains but does not encode the last such domain, the
transmembrane-spanning region or the intracellular tyrosine kinase domains (Kendall and Thomas, 1993;
Shibuya et al., 1990). The soluble form of VEGFR-1 is a heparin-binding protein (Kendall and Thomas,
1993).
Expression
At E7.5-E12.5 of mouse embryonic development, when the embryonic vasculature is established, VEGFR-
1 mRNA expression is detected in most if not all endothelia. During E14.5-E16.5 of fetal development, at a
time when endothelial differentiation is complete but blood vessel growth is still ongoing, VEGFR-1
expression is decreased (Peters et al., 1993). VEGFR-1 is also found in populations of embryonic cells
from which endothelium derives, such as early yolk sac mesenchyme (Peters et al., 1993). Expression of
VEGFR-1 mRNA in the quiescent endothelium of adult organs and in vessels near healing wounds
suggests that this receptor may have a role in the regulation of vascular permeability and in vascular repair
and maintenance (Peters et al., 1993).
VEGFR-1 is expressed in an endothelial cell-specific manner also in human fetuses (Kaipainen et al.,
1993). VEGFR-1 expression has not been extensively studied in lymphatic endothelial cells. However, in a
recent study, lymphatic vessels of the human fetal heart are found negative for VEGFR-1 protein
expression (Partanen et al., 1999a). According to one report VEGFR-1 is down regulated in the adult brain
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(Breier et al., 1995). Despite undetectable expression of VEGFR-1 in the normal adult rat brain, the same
receptor mRNA is observed in glioma tissues undergoing active angiogenesis (Plate et al., 1993). Besides
endothelial cells, monocytes express VEGFR-1 and both VEGF and PlGF stimulate tissue factor
production and chemotaxis in monocytes (Clauss et al., 1996). VEGFR-1 mRNA is also expressed in
human testis  (Ergun et al., 1997) and in bones (Plouet et al., 1989). Among the tumor cell lines studied,
only a few melanomas and leukemias aberrantly express VEGFR-1 (Cohen et al., 1995; Fiedler et al.,
1997). VEGFR-1 is upregulated in the angiogenic vascular endothelium of tumors (Hatva et al., 1995;
Shibuya, 1995). Hyperthyroidism, a disease accompanied by increased angiogenesis, also shows
upregulated VEGFR-1 mRNA expression (Sato et al., 1995).
VEGFR-1 is upregulated by hypoxia in vivo and in vitro (Brogi et al., 1996; Gerber et al., 1997; Li et al.,
1996; Marti and Risau, 1998; Tuder et al., 1995). The VEGFR-1 gene is also transiently expressed in
pericytes under hypoxic culture conditions (Nomura et al., 1995). The expression of VEGFR-1 is selectively
induced on dermal microvessels in skin explant cultures and in dermal endothelial cell monolayer cultures
under hypoxic conditions. VEGFR-2 is downregulated in the same experiment (Detmar et al., 1997).
Upregulation of VEGFR-1 but not VEGFR-2 under hypoxic conditions is demonstrated for HUVEC,
suggesting differential transcriptional regulation of the two receptors by hypoxia. The VEGFR-1 gene is
directly up-regulated by a hypoxia-inducible enhancer element located in the promoter of this receptor
(Gerber et al., 1997).
Signal transduction
VEGFR-1 encodes a receptor for VEGF, PlGF and VEGF-B (de Vries et al., 1992; Olofsson et al., 1998;
Park et al., 1994). In bovine adrenal cortex-derived capillary endothelial (ACCE) or HUVE cells PlGF is
unable to induce tyrosine autophosphorylation (Park et al., 1994). On the contrary, PlGF activates VEGFR-
1 autophosphorylation in transfected NIH3T3 cells (Sawano et al., 1996). More recently, PlGF is shown to
increase the level of tyrosine phosphorylation in porcine aortic endothelial (PAE)/VEGFR-1 cells to a higher
extent than VEGF treatment (Landgren et al., 1998).
Upon stimulation with VEGF VEGFR-1 expressing cells show an increased level of phosphorylation of
members of the Src tyrosine kinase family such as Fyn and Yes (Waltenberger et al., 1994). VEGF
induces phosphorylation of phospholipase C-gamma (PLC-γ), and GAP complex on tyrosine in VEGFR-1
transfected NIH3T3 cells as well as in endothelial cells (Seetharam et al., 1995). Strong activation of
mitogen activated protein kinase (MAPK) is detected only in endothelial cells and tyrosine phosphorylation
of SHC protein, an important adaptor for signal transduction for many receptor kinases, is very weak in
both cell types mentioned (Seetharam et al., 1995). In contrast, other studies report that VEGFR-1 fails to
31
activate MAPK whereas VEGFR-2 does (Kroll and Waltenberger, 1997). SCK which is one of many SHC
homologues, binds to VEGFR-1 via its SH2 domain (Igarashi et al., 1998). MAPK activation is delayed and
the mitogenic response is weaker in VEGFR-1 transfected fibroblasts when compared to endothelial cells
(Takahashi and Shibuya, 1997). SHP-2, PLC-γ, and GRB2 bind to the VEGFR-1 intracellular domain (Ito et
al., 1998). All VEGFRs are shown to be strong activators of signal transducers and activators of
transcription -3 and -5 (STAT3 and STAT5), and this suggests that they participate in the regulation of
endothelial function (Korpelainen et al., 1999). STATs are latent cytoplasmic transcription factors which
can specifically bind to tyrosine phosphorylated receptors through their SH2 domains. VEGFR-1 signal
transduction during vascular development appears to be insignificant (See below).
Biological effects
Mutant mice with targeted inactivation of VEGFR-1 gene, show disorganization of blood vessels and die at
day 8.5 of embryonic development (Fong et al., 1995). The loss of normal vascular organization is a
consequence of an overcrowded population of endothelial cells resulting from an increase in the number of
hemangioblasts. The primary cause for this effect is an alteration in cell fate determination among
mesenchymal cells (Fong et al., 1999). In contrast, VEGFR-1 tyrosine kinase-deficient homozygous mice
develop normal vessels and survive (Hiratsuka et al., 1998). However, VEGF-induced macrophage
migration is strongly suppressed in these mice. These results indicate that VEGFR-1 without a tyrosine
kinase domain is sufficient to allow embryonic development with normal angiogenesis, and that the main
role of this receptor is to act as a ligand binding molecule. VEGFR-1 having a higher affinity for VEGF than
VEGFR-2 but little transducing activity of its own (Park et al., 1994), can function as a negative regulator of
vasculogenesis and angiogenesis, by binding to free VEGF. Angiogenesis seems to be induced by a
combined activation of both VEGFR-1 and VEGFR-2, since PlGF/VEGF heterodimers are angiogenic in
contrast to PlGF homodimers (Kurz et al., 1998). However, the use of VEGF-E has demonstrated that
VEGFR-2 can potently mediate angiogenesis independently of VEGFR-1 activation (Meyer et al., 1999).
Soluble VEGFR-1 is able to inhibit tumor angiogenesis and growth in vivo, supporting the possibility of
using VEGFRs as antiangiogenic targets (Goldman et al., 1998; Kong et al., 1998).
3.1.b. VEGFR-2
Structure and chromosomal localization
A second receptor for VEGF, VEGFR-2 first named KDR (kinase insert-domain containing receptor)/flk-1
(fetal liver kinase-1) was cloned from a human endothelial cDNA library (Terman et al., 1991). This was
followed by the cloning of the mouse homologue fetal liver kinase 1 (Flk-1) also called NYK from cDNA
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libraries of mouse hematopoietic stem cells, neuroepithelium and embryonic stem cells (Matthews et al.,
1991; Oelrichs et al., 1993; Yamaguchi et al., 1993). The rat, quail and zebrafish homologues have also
been isolated (Eichmann et al., 1993; Sarzani et al., 1992; Sumoy et al., 1997).
The human gene encoding VEGFR-2 localizes in chromosomal region 4q11-q13 and the mouse
homologue is mapped to chromosome 5, near to the c-kit and PDGFR-A genes (Matthews et al., 1991;
Sait et al., 1995; Spritz et al., 1994; Terman et al., 1991). VEGFR-2 shares an overall structural
organization with VEGFR-1 (de Vries et al., 1992; Matthews et al., 1991; Shibuya et al., 1990; Terman et
al., 1991). Characterization of the human VEGFR-2 promoter reveals an endothelium-specific activating
element in the long 5´-untranslated region of the first exon. Negative regulatory elements are located
further upstream. The 5´-flanking region is rich in GC residues and lacks typical TATA or CAAT boxes
(Ronicke et al., 1996).
VEGFR-2 is a 230 kDa protein. Two VEGFR-2 mRNAs have been reported, a full-length prototypic form,
and a short form resulting from alternative splicing (Wen et al., 1998). Soluble VEGFR-1 forms a VEGF-
stabilized complex with the extracellular domain of VEGFR-2 in vitro (Kendall et al., 1996).
Expression
VEGFR-2 is a very early marker of endothelial cell precursors, as it is expressed in mesodermal cells prior
to any morphological evidence for endothelial cell differentiation (Yamaguchi et al., 1993). During mouse
embryonic development VEGFR-2 mRNA distribution is largely restricted to capillaries, blood vessels and
the endocardium (Millauer et al., 1993). During mouse brain angiogenesis VEGFR-2 is expressed in the
perineural vascular plexus and the invading vascular sprouts (Millauer et al., 1993). In the early postnatal
stages, when endothelial cell proliferation occurs, VEGFR-2 expression is evident but in the adult tissues
where the vascularization process is completed, the turnover of endothelial cells in parallel with VEGFR-2
expression, are low (Millauer et al., 1993). In most human fetal tissues examined VEGFR-2 is expressed in
an endothelial cell-specific manner (Kaipainen et al., 1993). VEGFR-2 is expressed in lymphatic
endothelial cells in the quail (Wilting et al., 1997), in the human fetal heart (Partanen et al., 1999a) and in
the skin of transgenic mice (Jeltsch et al., 1997).
Additionally, VEGFR-2 is expressed in hematopoietic stem cells, megakaryocytes, and platelets as well as
in retinal progenitor cells (Katoh et al., 1995; Yang and Cepko, 1996). Furthermore, VEGFR-2 mRNA is
detected in cells lining pancreatic ducts which are considered to contain precursor cells for the endocrine
pancreas (Oberg et al., 1994). Some melanoma and leukemia tumor cell lines express VEGFR-2 (Fiedler
et al., 1997; Liu et al., 1995). VEGF is expressed by all tumor cells studied whereas its receptor VEGFR-2
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localizes at the tumor associated vasculature suggesting a paracrine relationship between them (Ferrara
and Davis-Smyth, 1997; Klagsbrun and D´Amore, 1996; Shibuya, 1995). Unlike VEGFR-1, VEGFR-2 is not
expressed in pericytes (Detmar et al., 1997).
VEGFR-2 is upregulated by hypoxia in vivo (Li et al., 1996; Marti and Risau, 1998; Tuder et al., 1995), but
in vitro this receptor is either downregulated or not affected (Gerber et al., 1997; Takagi et al., 1996). In a
recent report, hypoxic treatment of endothelial cells had no effect on VEGF ligand binding, but medium
from hypoxic cell cultures indirectly increased ligand binding (Brogi et al., 1996). Postranscriptional
regulation seems to be responsible for upregulated VEGFR-2 production under hypoxic conditions
(Waltenberger et al., 1996). VEGFR-2 expression is upregulated on endothelial cells after VEGF treatment
(Kremer et al., 1997; Shen et al., 1998). Thus, the hypoxia-induced VEGFR-2 expression may be triggered
indirectly, since VEGF potentiates VEGFR-2 expression (Wilting et al., 1996).
Signal transduction
VEGFR-2 shows stronger tyrosine autophosphorylation compared to VEGFR-1 (Ito et al., 1998; Landgren
et al., 1998; Sawano et al., 1996; Seetharam et al., 1995; Waltenberger et al., 1994). To date, VEGF,
VEGF-C, VEGF-D and VEGF-E are shown to bind and induce tyrosine autophosphorylation of VEGFR-2
(Waltenberger et al., 1994; Joukov et al., 1996; Joukov et al., 1997; Achen et al., 1998; Ogawa et al.,
1998; Wise et al., 1999; Meyer et al., 1999). Only the final glycosylated form of VEGFR-2 is capable of
undergoing autophosphorylation in response to VEGF (Takahashi and Shibuya, 1997). Soluble forms of
VEGFR-2 have not been reported so far (Kendall et al., 1996). The identification of a heparin-binding site
in the extracellular domain of VEGFR-2 is consistent with the hypothesis that interactions between cell
surface HSPGs and the VEGF receptor contribute to maximal VEGF binding (Dougher et al., 1997).
Indeed, binding of VEGF to VEGFR-2 is stimulated by heparin (Terman et al., 1994; Roeckl et al., 1998).
VEGFR-2 is able to bind and phosphorylate PLC-γ  (Landgren et al., 1998). VEGF-induced stimulation of
VEGFR-2 results in the association and phosphorylation of SHC isoforms and the induction of SHC-GRB2
complex formation (Igarashi et al., 1998). A SHC homologue, SCK binds to VEGFR-2 via its SH2 domain
in a tyrosine kinase dependent manner (Igarashi et al., 1998). PKC is implicated in VEGF-induced MAPK
activation in VEGFR-2 transfected NIH3T3 fibroblasts (Takahashi and Shibuya, 1997). VEGFR-2 also
associates with GRB2 and NCK in a ligand-dependent fashion and VEGFR-2 stimulation is sufficient to
activate MAPK (Kroll and Waltenberger, 1997), STAT3 and STAT5 (Korpelainen et al., 1999).
34
Biological effects
It is possible that VEGFR-2 is the main vascular permeability regulator. VEGFR-1 may not be directly
involved in this process since VEGF is a potent inducer while PlGF-1 and PlGF-2 show twenty to forty fold
less activity in mediating vascular permeability (Dvorak et al., 1995; Park et al., 1994; Sawano et al., 1996).
Furthermore, VEGF-E is as potent as VEGF165 in inducing vascular permeability (Ogawa et al., 1998). In
the induction of protease activity such as uPA production, VEGF and PlGF are potent in VEGFR-1 but not
in VEGFR-2 expressing cells (Landgren et al., 1998). Although VEGFR-2 is expressed in lymphatic
endothelial cells VEGF homo- and heterodimers are not potent in inducing lymphangiogenesis (Wilting et
al., 1996; Oh et al., 1997). The formation of VEGFR-2  x VEGFR-3 heterodimers may be needed for the
lymphangiogenic effect exerted by VEGF-C.
VEGFR-2 is not necessary for hemangioblast commitment, but is required for subsequent expansion of the
lineage (Schuh et al., 1999). VEGFR-2 plays a pivotal role in endothelial development, being essential for
yolk-sac blood-island formation and vasculogenesis in the mouse embryo. VEGFR-2-null embryos die
between 8.5 and 9.5 days post-coitum, as a result of an early defect in the development of hematopoietic
and endothelial cells (Shalaby et al., 1995). VEGFR-2 seems to be involved in the movement of cells from
the posterior primitive streak to the yolk sac and hypothetically also to the intra-embryonic sites of early
hematopoiesis (Shalaby et al., 1997).
3.1.c. VEGFR-3
Structure and chromosomal localization
VEGFR-3 (FLT4) was cloned from human erythroleukemia (HEL) cell (Aprelikova et al., 1992; Pajusola et
al., 1993; Pajusola et al., 1992) and placenta cDNA libraries (Galland et al., 1992; Galland et al., 1993).
Mouse (Finnerty et al., 1993) and quail (Eichmann et al., 1996; Eichmann et al., 1993) homologues of
VEGFR-3 were cloned from embryonic cDNA libraries. The VEGFR-3 gene maps to chromosomal region
5q33-qter in humans (Aprelikova et al., 1992; Armstrong et al., 1993), close to the fms and PDGFR-β
genes (Warrington et al., 1991) and to chromosome 11 in mice (Watkins-Chow et al., 1997). The
extracellular domain of VEGFR-3 exhibits 33% and 37% amino acid sequence identity with VEGFR-1 and
VEGFR-2 respectively, whereas the tyrosine kinase identity is approximately 80% (Pajusola et al., 1992).
VEGFR-3 is expressed as mRNA forms of 4.5 and 5.8 kb, generated by alternative polyadenylation and
subsequent alternative splicing during RNA processing (Pajusola et al., 1993). The 3´coding region of the
5.8 kb mRNA is 65 amino acids longer and encodes the long form of VEGFR-3, whereas the 4.5 kb mRNA
encodes the short form. Only the longer from of VEGFR-3 is detected in human cell lines endogenously
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expressing VEGFR-3 proteins (Pajusola et al., 1993). Also only one mRNA form corresponding to the
longer VEGFR-3 is found in mouse tissues (Galland et al., 1993). VEGFR-3 polypeptides undergo post-
translational processing, which involves glycosylation and proteolytic cleavage to yield a mature receptor
composed of two polypeptides held together by disulfide bonds (Borg et al., 1995; Fournier et al., 1995;
Pajusola et al., 1994).
Expression
During early mouse development VEGFR-3 mRNA is expressed at E8.5 in the cardinal vein and in the
angioblasts of the head mesenchyme. During days 11.5-12.5 of development, the VEGFR-3 signal is more
prominent in the developing veins and presumptive lymphatic endothelia, with very weak if any positivity in
arterial endothelia. VEGFR-3 expression becomes confined to the lymphatic endothelium during day 14.5
of development (Kaipainen et al., 1995). Additionally, VEGFR-3 mRNA is detected in the endothelial cells
of the dorsal aorta in a E9.0 mouse embryos as well as in the yolk sac blood island endothelial cells
(Dumont et al., 1998).
VEGFR-3 is also expressed in quail embryos, e.g in the intra-embryonic vascular plexus in a 2-day old
embryo. In 3-day old embryos, all endothelial cells are positive but after that arteries become negative and
expression is restricted to the lymphatic vasculature. In the quail, also other than endothelial cells express
VEGFR-3 such as the cells of the notochord, podocytes of the kidney and some epithelial cells of the
gallbladder and extrahepatic bile ducts (Wilting et al., 1997).
Northern blot analysis of human fetal tissues reveals transcript distribution in all the tissues except the
thymus and small intestine, the highest levels being found in lung and spleen (Kaipainen et al., 1993;
Pajusola et al., 1992). In situ hybridization studies show VEGFR-3 expression in human fetal heart, lung,
kidney, mesenterium and gut (Kaipainen et al., 1993). In adults VEGFR-3 is expressed in the lymphatic
vessels of the lung, mesenterium and tonsil, while veins and arteries are negative (Kaipainen et al., 1995).
By Northern blotting, VEGFR-3 mRNA is detected in the placenta, lung, kidney, heart and liver in a
decreasing order (Aprelikova et al., 1992). Surprisingly, VEGFR-3 protein is detected by
immunohistochemistry in arterioles and venules as well as endothelial cells of capillaries in the nasal
mucosa of human adults (Saaristo et al., 1999).
The two VEGFR-3 mRNA forms are differentially expressed in the HEL and megakaryoblastic DAMI
leukemia cell lines. Additionally, a Wilms´tumor cell line, a retinoblastoma cell line and a nondifferentiated
teratocarcinoma cell line express VEGFR-3 (Pajusola et al., 1992). VEGFR-3 expression is demonstrated
also in cultured Kaposi´s sarcoma (KS) cells (Liu et al., 1997).
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Increased expression of VEGFR-3 mRNA is observed in the lymphatic sinuses of metastatic lymph nodes
and in lymphangioma, and in lymph nodes, it is also detected in high endothelial venules (HEV) (Kaipainen
et al., 1995). VEGFR-3 protein is found in the endothelium of lymphatic vessels around lymphomas. In
cutaneous nodular AIDS-associated KS the tumor cells as well as the endothelium around the nodules is
VEGFR-3 positive (Jussila et al., 1998). VEGFR-3 is expressed in lymphatic endothelia both in normal
breast and in breast carcinomas, but it is also weakly expressed in the blood capillary endothelium
showing enhanced expression in angiogenic capillaries (Valtola et al., 1999). VEGFR-3 is expressed
specifically in lymphatic vessels in normal tissues but not in different benign and malignant vascular tumors
where VEGFR-3 is not a specific marker for lymphatic endothelia. Proliferative neoplastic blood vessel
endothelia in general acquire VEGFR-3-expression independently of lymphatic vascular differentiation
(Partanen et al., 1999c). VEGFR-3 is detected in the fenestrated blood capillary endothelia of tissues with
extensive molecular exchange across the blood vessel wall (Partanen et al., 1999b).
Signal transduction
VEGFR-3 binds VEGF-C and VEGF-D. Upon stimulation, not only VEGF-C but also VEGF-D induces
strong VEGFR-3 autophosphorylation (Achen et al., 1998; Joukov et al., 1996). In the long form of
VEGFR-3, tyrosine 1337 is a potential autophosphorylation site (Fournier et al., 1996), and serves as
docking sites for GRB2 and SHC involved in VEGFR-3 signal transduction (Fournier et al., 1995).
In a HEL cell line expressing high levels of VEGFR-3, VEGF-C stimulation results in phosphorylation and
activation of the recently identified related adhesion focal tyrosine kinase RAFTK showing an enhanced
association of this kinase with the adaptor protein GRB2 (Wang et al., 1997). The tyrosine phosphorylated
molecules SHC, GRB2, and SOS have been found to form a signaling complex with the activated VEGFR-
3 (Wang et al., 1997). Upon stimulation of VEGFR-3 expressing cells, VEGF-C and VEGF-D induce rapid
tyrosine phosphorylation of the SHC protein and activation of the mitogen-activated protein kinases ERK1
and ERK2 (Taipale et al., 1999).
Biological effects
A VEGF-C mutant, which binds to and activates only VEGFR-3 and not VEGFR-2 does not induce
vascular permeability in vivo or stimulate migration of BCE cells in culture (Joukov et al., 1998). In contrast,
VEGF-C is shown to induce the proliferation of PAE/VEGFR-2 and PAE/VEGFR-3 cells in culture (Cao et
al., 1998). Cell shape changes and actin reorganization, as well as chemotactic responses are observed in
both VEGFR-3 and VEGFR-2 overexpressing cells upon VEGF-C stimulation (Cao et al., 1998).
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During mouse embryonic life VEGFR-3 has an essential role in the development of the cardiovascular
system before the emergence of the lymphatic vessels. In VEGFR-3-null embryos there are no major
defects in the differentiation of endothelial cells and in the process of vasculogenesis and angiogenesis.
However, vascular remodeling and maturation are abnormal in large vessels which have defective lumens.
Fluid accumulation occurs in the pericardial cavity, and cardiovascular failure at E9.5 (Dumont et al.,
1998). Additionally, the yolk sac vasculature is underdeveloped lacking major blood vessels because of a
failure of remodeling of the capillary network into complex vitelline vessels (Dumont et al., 1998).
3.1.d. NEUROPILIN
Structure
NP-1 gene encodes a transmembrane glycoprotein with a short (40 aa) highly conserved cytoplasmic tail
(Fujisawa et al., 1989; Takagi et al., 1987; Takagi et al., 1995; Kawakami et al., 1996). Due to the short
intracellular domain, lacking obvious docking sites, it is unlikely that NP-1 functions as an independent
receptor. NP-1 is expressed on the cell surface as a 130-140 kDa receptor (Soker et al., 1998). Neuropilin-
2 (NP-2) is closely related, having 47% homology to NP-1 (Kolodkin et al., 1997).
Ligand binding
NP-1 is a receptor for Collapsin-1/Semaphorin III/D (Sema III) family of proteins (Chen et al., 1997).
Semaphorins are a large family of secreted and transmembrane proteins, implicated in repulsive axon
guidance. NP-1 binds with high affinity to the three structurally related semaphorins Sema III, Sema E, and
Sema IV, whereas NP-2 shows high affinity binding only to Sema E and Sema IV, and not to Sema III
(Chen et al., 1997). Additionally, NP-1 binds VEGF165, PlGF-2, VEGF-B and VEGF-ENZ2but not VEGFR-1
or PlGF-1 (Soker et al., 1998; Migdal at al., 1998; Makinen et al., 1999; Wise et al., 1999). Binding of
VEGF165 to NP-1 occurs via the exon 7 encoded domain of VEGF (Soker et al., 1996; Soker et al., 1997),
whereas to VEGFR-2 and VEGFR-1 it involves exons 4 and 3 encoded domains (Keyt et al., 1996).
VEGF165 and collapsin-1 compete for NP-1-binding sites. Collapsin-1 inhibits the motility of PAE/NP-1 and
PAE/NP-1/VEGFR-2 cells, whereas VEGF165 stimulates the motility of PAE/NP-1/VEGFR-2 cells (Miao et
al., 1999). NP-1 binds PlGF-2 in a heparin-dependent manner (Migdal, et al., 1998), and acts as a VEGFR-
2 co-receptor (Soker et al., 1998). PlGF-1 and PlGF-2 have the same effect on the migration of endothelial
cells, which may mean that NP-1 does not function as a VEGFR-1 coreceptor. NP-1 and -2 form homo-
and heterooligomers (Chen et al., 1998).
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Expression
During mouse embryonic development, NP-1 is expressed in mesenchyme, heart, and limb buds
(Kitsukawa et al., 1995). Additionally, NP-1 is expressed in endothelial cells of capillaries and blood
vessels and in tumor cells (Kitsukawa et al., 1995; Soker et al., 1998). Furthermore, NP-1 is detected in
neurons during active axonal growth and is suggested to be involved in axonal fasciculation and guidance
(Kawakami et al., 1996). The NP-1 protein expression pattern is similar to that of VEGFR-1 in the human
fetal heart. NP-1 is expressed in all the vascular endothelial structures except in the lymphatic vessels
(Partanen et al., 1999a). NP-2 mRNA is expressed by developing neurons in a pattern partially overlapping
with that of NP-1 (Chen et al., 1997; Soker et al., 1998).
Biological effects
The targeted disruption of the NP-1 gene indicates the important role that NP-sematophorin III/D-mediated
chemorepulsive signals play in the guidance of peripheral nervous system (PNS) efferents and in nerve
fiber fasciculation (Kawakami, et al., 1996; Takagi, et al., 1995; Fujisawa, et al., 1997; He, et al., 1997;
Kolodkin, et al., 1997). Neuropilin-null mutant mice die after E12.5 dpc, and the homozygous mutant
embryos show severe abnormalities in the efferent fibers of the PNS. The lack of NP-1 expression primarily
affects nerve fiber guidance but not nerve fiber growth itself (Kitsukawa et al., 1997). Embryonic death is
probably attributable to anomalies in the cardiovascular system. This evidence supports the importance of
VEGF165 in NP-1 signaling (Kitsukawa et al., 1997).
Ectopic or excess expression of NP-1 under the control of the β-actin promoter in mice results in
morphological abnormalities in the tissues or organs in which this receptor is normally expressed
(Kitsukawa et al., 1995). Chimeric embryos overexpressing NP-1 exhibit excess capillaries and blood
vessels, ectopic sprouting and axonal defasciculation or extra digits, and these lesions are embryonic
lethal. These results reveal the essential role of NP-1 in the normal development of the cardiovascular
system, the nervous system and the limbs (Kitsukawa et al., 1995).
4. Vascular endothelial growth factors
VEGF was first described as a protein able to induce vascular permeability and endothelial cell proliferation
and it was identified as a major inducer of angiogenesis and vasculogenesis (Ferrara and Davis-Smyth,
1997). VEGF belongs to the PDGF/VEGF family of growth factors which also includes PlGF (Maglione et
al., 1991), VEGF-B (Olofsson et al., 1996a), VEGF-C (Joukov et al., 1996; Lee et al., 1996), VEGF-D
(Achen et al., 1998) and VEGF-E (Meyer et al., 1999; Ogawa et al., 1998). The members of this family are
structurally related growth factors. They are all dimeric glycoproteins sharing a number of biochemical and
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functional characteristics. Intra- and interchain disulphide bonds among eight characteristically spaced
cysteine residues are involved in the formation of the dimeric active proteins (Keck et al., 1989; Bussolino
et al., 1997). These factors bind and activate endothelial specific VEGFRs triggering signal transduction
(See Figure 4).
hPDGF-A M.RTLAC..LLLL..GCGYL.......AHVLAEEAEI.PREVIERLARSQIHSIRDLQRLLEIDSVGSE.....DSLDTSLRAHGVHATKHVP
hPDGF-B MNR..CWA.LFLS..LCCYL.......RLVSAEGDPI.PEELYEMLSDHSIRSFDDLQRLLHGDP.GEE.....DGAELDLNMTRSHSGGELE
hVEGF-C MHLL.GFFSVACSLLAAALLPGPREAPAAAAAFESGLDLSDAEPDAGEATAYASKDLEEQLRSVSSVDELMTVLYPEYWKMYKCQLRKGG.WQ
hVEGF-D MYR..EWVVVNVFMMLYVQL.........VQGSSNEHGPVKRSSQSTLERS......EQQIRAASSLEELLRITHSEDWKLWRCRLRLKS.F.
vVEGF-ENZ2 MKLLVGILVAVC..LHQYLL..........NA.............................................................
hVEGF165 MNFLLSWVHWSLALLL.YLHHAKW.....SQA.............................................................
hVEGF-B167 MSPLLRRLLLAA..LLQLAP.........AQ..............................................................
hPlGF-2 M.PVMR..LFPC..FLQLL.......AGLAL..............................................................
...................…...........................................................•
hPDGF-A EKRPLPIRRKRS...............I......EEAVPAVCKTRTVIYEIPRSQVDPTSANFLIWPPCVEVKRCTGCCNTSSVKCQPSRVHH
hPDGF-B S....LARGRRS...............LGSLTIAEPAMIAECKTRTEVFEISRRLIDRTNANFLVWPPCVEVQRCSGCCNNRNVQCRPTQVQL
...................…...................................................................•
hVEGF-C HNREQANLNSRTEE..TIKFAAAHYNTEILKSIDNEWRKTQCMPREVCIDVGKEFGVAT..NTFFKPPCVSVYRCGGCCNSEGLQCMNTSTSY
...................…...................................................................•
hVEGF-D .....TSMDSRSASHRSTRFAATFYDIETLKVIDEEWQRTQCSPRETCVEVASELGKST..NTFFKPPCVNVFRCGGCCNEESLICMNTSTSY
...................…........................................................................•
vVEGF-ENZ2 .........................DSNTKGWSE.VLKGSECKPRPIVVPVSETHPELT..SQRFNPPCVTLMRCGGCCNDESLECVPTEEVN
...................…........................................................................•
hVEGF165 .......APMAE........GGGQNHHEVVKFMD.VYQRSYCHPIETLVDIFQEYPDEI..EYIFKPSCVPLMRCGGCCNDEGLECVPTEESN
hVEGF-B167 .......APVSQP.......DAPGHQRKVVSWID.VYTRATCQPREVVVPLTVELMGTV..AKQLVPSCVTVQRCGGCCPDDGLECVPTGQHQ
.....................•......................................................................•
hPlGF-2 .......PAVPPQQWALSA.GNGSSEVEVVPFQE.VWGRSYCRALERLVDVVSEYPSEV..EHMFSPSCVSLLRCTGCCGDENLHCVPVETAN
hPDGF-A RSVKVAKVEYVRKKPKLKEVQVRLEEHLECACATTSLNPDYREEDTDVR*
hPDGF-B RPVQVRKIEIVRKKPIFKKATVTLEDHLACKCETVAAARPVTRSPGGSQEQRAKTPQTRVTIRTVRVRRPPKGKHRKFKHTHDKTALKETLGA*
.........................•
hVEGF-C LSKTLFEITVPLSQGP.KPVTISFANHTSCRCMSKLDVYRQVHSIIRRSLP.ATLPQCQAANKTCPTNYMWNNHICRCLAQEDFMFSSDAGDD
.........................•
hVEGF-D ISKQLFEISVPLTSVP.ELVPVKVANHTGCKCLPTAP..RHPYSIIRRSIQIPEEDRCSHSKKLCPIDMLWDSNKCKCVLQEENPL.AGTEDH
vVEGF-ENZ2 VSMELLGASGSGSNGMQR...LSFVEHKKCDCRPRFTTTPPTTTRPPRRRR*
hVEGF165 ITMQIMRIKPH..QGQ.HIGEMSFLQHNKCECRPKKDRARQENPCGP..............................................
hVEGF-B167 VRMQILMIRYPSSQ....LGEMSLEEHSQCECRPKKKDSAVKPDSPRPLCPR.........................................
hPlGF-2 VTMQLLKIRSG..DRP.SYVELTFSQHVRCECRPLREKMKPERRRPKGRGKRRREKQRPTDCHLCGDAVLRR*
hVEGF-C STDGFHDICGPNKELDEETCQCVCRAGLRPASCGPHKELDRNSCQCVCKNKLFPSQCGANREFDENTCQCVCKRT..................
hVEGF-D S............HLQE....................................PALCGPHMMFDEDRCECVCKTP..................
hVEGF-C CP...RNQ.PLNPGKCAC.ECTESPQKCLLKG.KKFHHQTCSCYRRPCTNRQKACEPGFSYSEEVC.R.CVPSYWKRPQMS*
..............•
hVEGF-D CP...KDL.IQHPKNCSCFECKESLETCCQKH.KLFHPDTCSCEDR.CPFHTRPCASG..KT..ACAKHCRFPKEKRAAQGPHSRKNP*
hVEGF165 CSERRKHLFVQDPQTCKC.SCKNTDSRCKARQ.LELNERTCRCDKPRR*
hVEGF-B167 CTQH..HQRP.DPRTCRC.RCRRRSFLRCQGRGLELNPDTCRCRKPRR*
Fig. 5. Amino acid sequence alignment of the VEGF and PDGF family members. Small black spots
appearing above the sequence indicate (potential) glycosylation sites. Bold letters refer to VEGF homology
domain. Gray letters mark the signal sequence and underlined parts indicate the Balbiani ring 3 protein
regions. Boxes with gray background mark the invariant amino acids and black boxes indicate the invariant
cysteines.
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4.1. VEGF
Structure and functional properties
VEGF is a basic, 34-46-kDa homodimeric, heparin-binding glycoprotein, with its amino acid sequence
being approximately 20% identical with PDGF A and B chains (Conn et al., 1990; Ferrara et al., 1992;
Keck et al., 1989; Leung et al., 1989; Tischer et al., 1989). VEGF is also known as vascular permeability
factor (VPF) or vasculotropin, and was originally purified as a tumor cell secreted protein (Connolly et al.,
1989; Senger et al., 1987; Senger et al., 1990; Senger et al., 1983; Senger et al., 1986; Senger et al.,
1993). The human VEGF gene is located in chromosomal region 6p21.3 (Vincenti et al., 1996) and its
coding region spans approximately 14 kilobases (kb). The VEGF gene in humans is organized into eight
exons, separated by seven introns (Houck et al., 1991; Tischer et al., 1991). A single VEGF gene is
alternatively spliced generating five different molecular species of mRNA, encoding putative proteins of
121, 145, 165, 189 and 206 amino acids (Ferrara et al., 1997; Poltorak et al., 1997). VEGF165 is the
predominant form produced in many normal and tumor cells, whereas VEGF206 is the rarest form. VEGF121
and VEGF165 are secreted in soluble form, though a significant fraction of VEGF165 remains bound to the
cell surface or the ECM. The binding of VEGF isoforms to cell surfaces and ECM occurs via interactions
with HSPG and reflects the differential heparin-binding capabilities of the VEGF isoforms. VEGF121 is a
weakly acidic protein which doesn’t bind to heparin, whereas VEGF165 binds to immobilized heparin. The
larger isoforms VEGF189 and VEGF206 remain cell-associated, or sequestered in the ECM, maybe because
of their greater affinity for HSPG but can be released and activated by soluble heparin or heparinase
(Houck et al., 1992; Park et al., 1993; Peretz et al., 1992).
Receptor binding
VEGF binds to specific receptor tyrosine kinases, VEGFR-1 and VEGFR-2 (De Vries et al., 1992; Quinn et
al., 1993). Cell surface-associated heparin-like molecules regulate the binding of VEGF to its receptors
(Gitay-Goren et al., 1992). Recently NP-1 has been shown to bind VEGF165. When coexpressed in cells
with VEGFR-2, NP-1 enhances VEGF165 binding to VEGFR-2 and its chemotactic and mitogenic activity
(Soker et al., 1998). The binding of VEGF165 to NP-1 is strongly enhanced by the addition of exogenous
heparin (Soker et al., 1998; Gitay-Goren et al., 1992).
Expression
During mouse embryonic development VEGF mRNA is detected as early as E7.0 in both the extra-
embryonic and embryonic endoderm. At E8.0 VEGF mRNA is expressed in the yolk sac endoderm, the
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mesothelium of the allantois and in the giant cells of the trophoblast layer (Breier et al., 1995; Jakeman et
al., 1993). At later developmental stages in the mouse or rat embryos VEGF mRNA is observed in the
choroid plexus epithelium, the vertebral column, along the surface of the spinal cord, in the ventricular
layers of the brain and in the glomerular epithelium of the kidney (Breier et al., 1992; Jakeman et al.,
1993). A certain subtype of endothelial cells, i.e., the endocardium, and cells in the outflow tract of the
heart are positive for VEGF (Miquerol, et al., 1999). In the quail embryo, VEGF expression is detected in
the endothelium of the aorta close to the heart, suggesting a potential autocrine regulation (Aitkenhead et
al., 1998). In the adult rat VEGF mRNA is expressed in the brain, kidney, lung, liver and spleen,
suggesting a role in the maintenance of normal vessel physiology (Ferrara et al., 1992). In the human fetus
VEGF mRNA expression is detectable in all the tissues and is most abundant in lung, kidney, and spleen
(Shifren et al., 1994). VEGF protein is localized in epithelial cells and myocytes, but not vascular
endothelial cells (Shifren et al., 1994). VEGF is also produced by macrophages, T cells, smooth muscle
cells, kidney cells, mesangial cells, keratinocytes, astrocytes, osteoblasts and tumor cells (Klagsbrun and
D´Amore, 1996).
Regulation of expression
VEGF expression is regulated by a variety of hormones, growth factors and cytokines. VEGF mRNA levels
are increased in cultured cells by IL-6 (Cohen et al., 1996), PDGF (Finkenzeller et al., 1992), EGF
(Goldman et al., 1993), TGF-β (Pertovaara et al., 1994), KGF (Frank et al., 1995), prostaglandin E2
(Harada et al., 1995), Il-1-β (Ben-Av et al., 1995), thyroid stimulating hormone (Soh et al., 1996) and
luteotrophic hormone (Garrido et al., 1993). Additionally, phorbol ester (Finkenzeller et al., 1992; Garrido et
al., 1993), nitric oxide (Tuder et al., 1995) and the products of v-Has-ras and v-raf oncogenes (Grugel et
al., 1995) potently induce VEGF expression.
Hypoxia is a fast and strong inducer of VEGF mRNA expression in a variety of normal and transformed in
vitro cell types (Minchenko et al., 1994; Shima et al., 1995). The same effect takes place in vivo under the
hypoxic conditions generated around necrotic regions of tumors (Plate et al., 1994; Shweiki et al., 1992),
as well as during ischemia caused by occlusion of the coronary artery in pig and rat (Banai et al., 1994;
Hashimoto et al., 1994). Hypoxic up-regulation of VEGF mRNA in neuroglial cells, secondary to the onset
of neuronal activity, plays an important physiological role in the development of the retinal vasculature
(Stone et al., 1995). VEGF gene promoters have cis-acting enhancer elements to which the hypoxia-
inducible factor (HIF) binds, mediating hypoxia-induced transcriptional activation (Levy et al., 1995; Liu et
al., 1995; Wang et al., 1995; Wang and Semenza, 1995). Increased mRNA stability is identified as a
significant post-transcriptional component in upregulating VEGF (Ikeda et al., 1995; Levy et al., 1996).
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Bioactivity
VEGF stimulates the migration and proliferation of arterial, venous, and microvascular endothelial cells and
induces angiogenesis in vitro and in vivo (Connolly et al., 1989; Ferrara and Davis-Smyth, 1997; Leung et
al., 1989; Plouet et al., 1989). Similarly, VEGF stimulates migration of monocytes/macrophages which
display VEGFR-1 on their surface (Barleon et al., 1996; Clauss et al., 1990; Clauss et al., 1996). In
contrast, PAE cells expressing VEGFR-1 after transfection fail to migrate towards VEGF, whereas
PAE/VEGFR-2 cells, proliferate, migrate, show actin reorganization, and changes in cell morphology when
stimulated with the same factor (Waltenberger et al., 1994). The angiogenic activity of VEGF is studied in
many in vivo models, for example the CAM assay (See table on page 17 and Leung et al., 1989; Plouet et
al., 1989). In addition, VEGF acts as a survival factor for serum deprived endothelial cells (Gerber et al.,
1998a; Gerber et al., 1998b). Acting as a pro-survival factor, VEGF stimulates the expression of the anti-
apoptotic proteins Bcl-2 and A1 in human endothelial cells (Gerber et al., 1998a). Endothelial cell
dependence on VEGF is controlled by the presence of pericytes (Benjamin et al., 1998). Furthermore,
VEGF induces vascular leakage as indicated in the Miles assay (Dvorak et al., 1995).
Biological role
Inactivation of the VEGF gene in mice results in embryonic lethality in heterozygous embryos, between day
11 and 12. These mice are growth retarded and have developmental anomalies (Carmeliet et al., 1996;
Ferrara et al., 1996). In the heart, the outflow region is malformed, the dorsal aorta is rudimentary and the
thickness of the ventricular wall is decreased. The yolk sac blood islands have a reduced number of
nucleated red blood cells. The vitelline veins fail to fuse with the vascular plexus of the yolk sac. The
vasculature shows defects in the placenta and the nervous system. Blood vessel ingrowth fails to the
neuroepithelium and the forebrain region appears underdeveloped. VEGF heterozygous mice survive two
days longer than VEGFR-1 and VEGFR-2 null embryos due to partial activation of these receptors by
VEGF. The homozygous VEGF mice have a strikingly reduced number of vessels, showing a much less
complex branching pattern if compared to the VEGF heterozygous mice. At E8.5 the dorsal aorta is absent
and the endothelial cell development is delayed resulting into death at E10.5 (Carmeliet et al., 1996).
VEGF deficiency impaired most steps of early vascular development, including in situ differentiation of
blood islands and angiogenesis. Several factors may contribute to this phenotype, including abnormal
accumulation or delayed differentiation of endothelial cells (Carmeliet et al., 1996; Ferrara et al., 1996). In
contrast embryos lacking VEGFR-2 die due to the lack of formation of both endothelial cells and
hematopoietic cells (Shalaby et al., 1995), as a result of the blocked migration of angioblasts to the initial
embryonic sites of vasculogenesis (Shalaby et al., 1997). VEGFR-2 null embryos lack vasculogenesis and
fail to develop blood islands (Shalaby et al., 1995). Organized blood vessels fail to develop throughout the
43
embryo and yolk sac, resulting in death between day 8.5 and 9.5 (Shalaby et al., 1995). This difference in
the VEGF and VEGFR-2 deficient mice suggests that a VEGF related factor would compensate for VEGF
loss. Endothelial cells develop in VEGFR-1 deficient mice but these embryos die as a result of severe
defects in the organization of the primitive vascular system (Fong et al., 1995). In these mice the
endothelial cells develop in both embryonic and extra-embryonic sites but fail to organize in normal
vascular channels (Fong et al., 1995). Changes in the cell fate determination among mesenchymal cells
with increased hemangioblast commitment and an overproduction of endothelial cells are the primary
defects in these knockout mice which die between days 8.5 and 9.5 (Fong et al., 1999). Thus, VEGF and
its receptors are essential for blood island development and angiogenesis. VEGF is the most critical player
since reduced concentrations are inadequate to support normal development, suggesting a tight dose-
dependent regulation of embryonic vessels development by VEGF (Carmeliet et al., 1996). Embryonic
lethality occurs even in the heterozygous state (Ferrara et al., 1996).
There seems to be functional complementarity of the VEGF isoforms in angiogenesis, since mice
expressing only the VEGF120 isoform show impaired myocardial angiogenesis and ischemic
cardiomyopathy (Carmeliet et al., 1999). Specific isoforms may be important for an optimal angiogenic
response in vivo. VEGF-C expression in the VEGF120 mice is reduced and since this factor is also
angiogenic in settings of tissue ischemia (Witzenbichler et al., 1998) the lower VEGF-C levels may have
contributed to the impaired postnatal angiogenesis. Overexpression of VEGF during quail development
results in hyper-vascularity and hyper-permeability (Flamme, 1995). On the other hand, VEGF
administered during the onset of vasculogenesis in quails results in abnormal development and an
excessive fusion of vessels (Drake and Little, 1995).
4.2. Placenta growth factor PlGF
Structure and functional properties
PlGF was initially cloned from a human placental cDNA library and is a 149-amino-acid-long protein. It is a
N-glycosylated, homodimeric, secreted protein (Maglione et al., 1991). Alternative splicing generates three
PlGF forms (Cao et al., 1996; Hauser and Weich, 1993; Cao et al., 1997). The smaller isoform is called
PlGF-1 and has a 20-amino acid signal peptide that is cleaved to yield a 129-residue mature protein. The
large isoform PlGF-2, differs from the other two PlGF forms by the insertion of a highly basic 21-amino acid
stretch at the carboxyl-end of the protein which confers to it its heparin binding ability (Hauser and Weich,
1993). The third isoform, PlGF-3, was cloned by the polymerase chain reaction technique, using a human
cDNA library prepared from the placental tissue of term pregnancy (Cao et al., 1997). PlGF-3 contains an
in-frame insertion of 72-amino acids near the C-terminal portion of PlGF-1. Transient expression of PlGF-3
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cDNA in mammalian cells results in the secretion to the conditioned medium as dimers and monomers
(Cao et al., 1997). The PlGF gene is assigned to human chromosome 14q24-q31 (Mattei et al., 1996) and
mouse chromosome 12q (DiPalma et al., 1996). Naturally occurring and secreted PlGF/VEGF
heterodimers are detected in conditioned media of tumor cell lines (Cao et al., 1996; Park et al., 1994).
Receptor binding
PlGF-1 and PlGF-2 do not interact with VEGFR-2 but are able to bind to VEGFR-1 (Kendall et al., 1994;
Park et al., 1994; Terman et al., 1994). Only PlGF-2 binds NP-1 in a heparin-dependent manner (Migdal et
al., 1998).
Expression
During mouse embryonic development no mRNA expression of PlGF intra-embryonally is detected
(Persico et al., 1999). Extra-embryonally, PlGF is expressed in the villous trophoblasts, whereas VEGF is
found in cells of mesenchymal origin within the chorionic plate (Vuorela et al., 1997). Thus, placental cells
produce only homodimeric PlGF (Vuorela et al., 1997). Mouse PlGF mRNA is detected at high levels in the
placenta and at lower levels in the lung and thyroid (DiPalma et al., 1996). Immunohisto-chemistry shows
PlGF expression in the vasculosyncytial membrane and in large blood vessels of the placental villi (Khaliq
et al., 1996). Northern blot analysis shows low transcript levels in human thyroid, heart, brain, lung and
skeletal muscle (Maglione et al., 1993; Viglietto et al., 1995). PlGF mRNA is abundant in the placenta,
cultured human endothelial cells, such as HUVECs, trophoblastic tumors such as choriocarcinoma (JAR
and JEG-3), and hepatoma HepG2 cells (Cao et al., 1996; Hauser and Weich, 1993; Maglione et al., 1991;
Maglione et al., 1993).
PlGF mRNA levels are not increased during hypoxia (Cao et al., 1996; Viglietto et al., 1996). Under
hypoxic conditions there is an increase in PlGF homodimers, but this can be explained by post-
transcriptional regulation (Maglione et al., 1993). In the proposed post-transcriptional control mechanism of
PlGF expression, the elimination of the 5´ untranslated region (UTR) of PlGF mRNA increases PlGF
synthesis (Maglione et al., 1993).
Biological activity and role
There seems to be disagreement regarding the biological activities of PlGF. PlGF is mitogenic for calf
pulmonary arterial (CPA) endothelial cells in vitro (Maglione et al., 1991). Similarly, PlGF induces
mitogenicity but not migration of VEGFR-1 expressing PAE cells (Landgren et al., 1998). In contrast, in
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ACCE or HUVE cells PlGF isoforms have no direct mitogenic or permeability-enhancing activity on their
own but are able to potentiate the action of VEGF in vitro and in vivo (Park et al., 1994). However, still
another study demonstrates that PlGF-1 and especially PlGF-2, induce proliferation of endothelial cells,
angiogenesis, and permeability (Sawano et al., 1996; Ziche et al., 1997). The heterodimers composed of
VEGF and PlGF subunits exert mitogenic activity almost as potent as VEGF homodimers on HUVE cells.
In the same study, PlGF homodimers appear inactive and might be mitogenic only at high, possibly non-
physiological concentrations (DiSalvo et al., 1995). Furthermore, in separate experimental settings PlGFs
induce the migration of cells expressing VEGFR-1, such as monocytes and endothelial cells (Clauss et al.,
1996). PlGF elicits an angiogenic response in the avascular rabbit cornea and in the CAM assay (Ziche et
al., 1997). Instead, in another report PlGF-1 shows no angiogenic activity in the mouse cornea (Cao et al.,
1996). Similarly, PlGF-1 and PlGF-2 have no angiogenic (Birkenhager et al., 1996; Oh et al., 1997) or
lymphangiogenic effect (Oh et al., 1997) in the CAM assay.
Inactivation of the PlGF gene does not result in embryonic lethality, even in the homozygous state
(Carmeliet and Collen, 1999). PlGF -/- mice are viable and fertile, although they may have some
impairment of wound healing (Carmeliet and Collen, 1999).
4.3. VEGF-B
Structure and functional properties
Mouse VEGF-B was isolated from E14.5 embryonic and newborn brain cDNA libraries (Olofsson et al.,
1996a; Townson et al., 1996). The human VEGF-B was cloned from a fibrosarcoma and a fetal brain
cDNA libraries (Olofsson et al., 1996a; Grimmond et al., 1996). Two VEGF-B isoforms are generated by
alternative splicing of mRNA from a single gene. The first one identified, VEGF-B167, encodes 167 amino
acids whereas the second isoform VEGF-B186 encodes 186 amino acid residues (Olofsson et al., 1996b).
The NH2-terminal domains of the two VEGF-B isoforms are identical, whereas the COOH-terminal parts
show no resemblance (Olofsson et al., 1996a; Olofsson et al., 1996b). Both isoforms show strong
homology to VEGF at their amino termini. Both the human and mouse VEGF-B genes consist of seven
coding exons and span about 4 kilobases of DNA (Olofsson et al., 1996b). Human VEGF-B gene maps to
the D11S750 marker at chromosomal band 11q13 (Grimmond et al., 1996; Paavonen et al., 1996). VEGF-
B186 does not contain the highly basic and cysteine-rich COOH-terminal heparin binding domain found in
VEGF-B167. This results in the free secretion of the longer isoform from cells so that it will not remain bound
to cellular or pericellular HSPGs (Olofsson et al., 1996b). Within the PDGF/VEGF family of growth factors,
VEGF-B186 represents the first isoform, which is modified by O-linked glycosylation. VEGF-B186, like VEGF-
B167 is secreted as a disulfide-linked homodimer able to form disulfide-linked heterodimers with VEGF
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(Olofsson et al., 1996b). VEGF-B167 is also secreted, but due to its strong affinity for HS, it remains cell-
surface-associated. Amino acid sequence comparisons reveal that VEGF-B shares approximately 45%
identity with VEGF (Olofsson et al., 1996a; Olofsson et al., 1996b). Proteolytic processing of the 60-kDa
VEGF-B186 dimer results in a 34-kDa dimer containing the receptor-binding epitopes (Olofsson et al.,
1998b).
Receptor binding
VEGF-B167 and VEGF-B186 were transfected into 293-T cells and metabolically labeled conditioned medium
from these cells was used to investigate binding to VEGFR Ig fusion proteins. Both VEGF-B isoforms bind
to VEGFR-1 selectively. Binding is blocked by excess VEGF, suggesting partially overlapping interaction
sites on the receptor (Olofsson et al., 1998). Conditioned medium from mouse VEGF-B186 baculovirus-
infected cells was used to assay VEGF-B binding to cell-surface-expressed VEGFR-1. VEGF-B competed
for 125I-VEGF binding to NIH 3T3-VEGFR-1 cells (Olofsson et al., 1998). VEGF-B167 and the processed but
not the full-length form of VEGF-B186 bind also NP-1 (Makinen et al., 1999).
Expression
During mouse embryonic development VEGF-B mRNA is distributed in the heart, spinal cord, cerebral
cortex, brown fat and skeletal muscle (Lagercrantz et al., 1996; Olofsson et al., 1996a). Expression in the
heart is consistent throughout development (Olofsson et al., 1996a; Olofsson et al., 1996b). Northern
blotting analysis reveals VEGF-B expression in mouse heart, brain, skeletal muscle and kidney. In human
tissues the VEGF-B transcript is detected in the heart, skeletal muscle, pancreas and prostate.
Glioblastomas, breast carcinomas and renal cell carcinomas were assayed for possibly increased VEGF-B
levels (Grimmond et al., 1996). Elevated transcription was not found in any of these tumors when
compared with their normal counterparts or non-malignant cell lines (Grimmond et al., 1996). Serum and its
component growth factors as well as pro-inflammatory cytokines did not stimulate VEGF-B mRNA
expression in vitro. Furthermore, hypoxia, Ras oncoprotein and mutant p53 tumor suppressor did not
increase VEGF-B mRNA levels (Enholm et al., 1997; Ristimäki et al., 1998).
Biological activity and role
Conditioned medium containing human VEGF-B167 collected from human embryo kidney 293EBNA cells
transfected with the appropriate expression vector, stimulated proliferation of HUVE and BCE cells
(Olofsson et al., 1996a). This stimulation of DNA synthesis might be explained by heterodimer formation
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with VEGF as, in additional experiments, a mitogenic effect was not obtained by using the purified
recombinant human VEGF-B186 expressed in Pichia pastoris (personal communication Dr B. Olofsson).
The function of VEGF-B though is still unclear, and even knockout mice show no obvious abnormalities,
they are viable and fertile (U. Eriksson and collaborators, unpublished observations). These results imply
that VEGF-B does not play a major independent role in vascular development. It is possible that VEGF-B
modulates the biological activities of VEGF, either by forming heterodimers or by potentiation of its
biological activities, as suggested for PlGF. Both VEGF-B isoforms are able to form homodimers and to
heterodimerize with VEGF, and perhaps with other similar growth factors, and this adds to the diversity of
their biological roles by allowing a variety of combinations for cellular signal transduction. Similarly, no
specific phenotype is detected in transgenic mice overexpressing VEGF-B in the basal layer of the skin or
in the heart (unpublished data of Michael Jeltsch and Kari Alitalo).
4.4. VEGF-C
Structure and functional properties
VEGF-C was cloned from the human prostatic adenocarcinoma cell line (PC-3) (Joukov et al., 1996) and
human glioma cell line (G61) cDNA libraries (Lee et al., 1996). The avian VEGF-C was from a E4 quail
cDNA library (Eichmann et al., 1998). The murine was cloned from a murine embryonic liver cell line (Fitz
et al., 1997). The VEGF-C gene is located on chromosome 8 (Chilov et al., 1997; Fitz et al., 1997) and
human chromosome 4q34 (Paavonen et al., 1996). Both human and mouse VEGF-C genes comprise over
40 kb of genomic DNA and consist of seven exons, all containing coding sequences (Chilov et al., 1997).
Human VEGF-C cDNA encodes a preproprotein of 419 amino acid residues, with a predicted molecular
mass of 46.9 kDa. The newly synthesized VEGF-C product is a pre-pro-protein, consisting of an N-terminal
signal sequence followed by an N-terminal peptide, the VEGF-homology domain, and a C-terminal pro-
peptide (Joukov et al., 1996). VEGF-C is secreted as a disulphide bonded homodimer, and most of it is
proteolytically processed from the precursor polypeptide, which contains three putative N-glycosylation
sites; two of these remain in mature, fully processed VEGF homology domain (Joukov et al., 1996). VEGF-
C is first synthesized as a 58kDa precursor, most of which undergoes dimerization before secretion into
the culture medium. It is then further cleaved, forming disulfide-linked 29 and 31kDa polypeptides, and
rapidly secreted. These complexes are further cleaved after secretion into 15 and 21kDa polypeptides.
Comparison of the obtained sequences with the sequence of the VEGF-C precursor indicates that the 15
and 31kDa polypeptides correspond to the N-terminal region of the secreted VEGF-C after cleavage of the
signal peptide. The 29kDa form represents the C-terminal half of the VEGF-C precursor. The 21kDa form
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is generated by cleavage of the VEGF-C precursor. Mature polypeptides of 21 and 31kDa contain the
entire VEGF homology domain with all eight conserved cysteine residues and two putative N-glycosylation
sites (Joukov et al., 1997). The VEGF homology domain of VEGF-C is encoded by exons 3 and 4,
whereas exons 5 and 7 encode cysteine-rich motifs and exon 6 encodes motifs typical of a silk protein
(Chilov et al., 1997).
Receptor binding
The stepwise proteolytic processing of VEGF-C generates several VEGF-C forms with increased binding
and activity towards VEGFR-3 and VEGFR-2. Non-processed VEGF-C preferentially binds to and activates
VEGFR-3, whereas only the fully processed mature form of VEGF-C is a high affinity ligand and an
activator of both VEGFR-3 and VEGFR-2 (Joukov et al., 1997). A VEGF-C site-directed mutant has been
generated. It binds and activates VEGFR-3, but not VEGFR-2 (Joukov et al., 1998). The use of a truncated
VEGF-C derivative reveals that its receptor-binding capacity resides in the portion of the molecule that is
most closely related in primary structure to the other VEGF family members. This corresponds to the
mature form of VEGF-C (Achen et al., 1998; Joukov et al., 1996).
Expression
In the quail VEGF-C mRNA is strongly expressed in regions destined to be rich in lymphatic vessels,
particularly the mesenteries, in the region surrounding the jugular veins and the kidney (Eichmann et al.,
1998). Northern analysis reveals VEGF-C expression most prominently in human heart, placenta, muscle,
ovary and small intestine. Very little VEGF-C RNA is seen in the brain, liver or thymus (Joukov et al., 1996;
Lee et al., 1996). Additionally, transcripts are detected in human spleen, lymph node, thymus, appendix,
bone marrow and fetal liver (Fitz et al., 1997). Tumor cells like HT-1080 fibrosarcoma, PC-3 prostatic
adenocarcinoma and G61 glioma cell lines express VEGF-C mRNA (Joukov et al., 1996; Lee et al., 1996).
The upstream promoter sequences contain conserved putative binding sites for Sp-1, AP-2, and NF-kB
transcription factors but no TATA box. The VEGF-C gene promoter does not contain putative binding sites
for hypoxia-regulated factors (Chilov et al., 1997). VEGF-C mRNA levels are increased after stimulation of
cultured cells by angiogenic proinflammatory cytokines (Ristimäki et al., 1998). This is mainly due to
enhanced transcriptional activation rather than mRNA stability. Hypoxia, Ras oncoprotein and mutant p53
tumor suppressor, which are potent inducers of VEGF mRNA do not increase VEGF-C mRNA levels
(Enholm et al., 1997).
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Biological activity and role
VEGF-C increases vascular permeability as well as the migration and proliferation of endothelial cells
(Joukov et al., 1997). The importance of VEGFR-2-mediated signal transduction appears to be critical for
the vascular permeability activity of VEGF-C, and it is strongly suggested that the redundant biological
effects of VEGF and VEGF-C depend on binding and activation of VEGFR-2 (Joukov et al., 1998). On the
other hand, the fact that the effects of VEGF-C on blood vasculature of the mature CAM are minor (Oh et
al., 1997), suggests that the signal for lymphatic angiogenesis is mediated by VEGFR-3, or its
heterodimeric complex with VEGFR-2. This is also in good accord with the VEGF-C characteristic of being
less potent that VEGF in stimulating the DNA synthesis of capillary endothelial cells (Joukov et al., 1996;
Lee et al., 1996).
VEGF-C promotes the mitogenesis of human lung capillary endothelial cells (Lee et al., 1996). These
experiments fail to distinguish whether the mitogenic effect is due to activation of VEGFR-3, or VEGFR-2.
Evidence comes from a recent experiment (Cao et al., 1998) showing the potential of VEGF-C to stimulate,
in a dose-dependent manner, the growth of PAE/VEGFR-3 cells. Recently VEGF-C was shown to exhibit a
dose-dependent mitogenic and chemotactic effect on endothelial cells, particularly for microvascular
endothelial cells (Witzenbichler et al., 1998). VEGF-C stimulates nitric oxide release from endothelial cells,
increased vascular permeability and, in vivo, angiogenesis in the setting of limb ischemia (Witzenbichler et
al., 1998). In addition, VEGF-C elicits angiogenic effects in limbal vessels in the mouse cornea and in CAM
(Cao et al., 1998). Thus, VEGF-C can be involved in the regulation of physiological and pathological blood
vessel growth.
Overexpression of VEGF-C in the skin of transgenic mice results in lymphatic, but not vascular endothelial
proliferation and vessel enlargement (Jeltsch et al., 1997). Similar results are obtained with VEGF-C
application to the mature CAM, resulting in a robust lymphangiogenic response but only a weak angiogenic
response (Oh et al., 1997). It is possible that different responses are obtained depending on whether
VEGF-C administration is topical or systemic in the transgenic mice. Depending on the spatial and
temporal expression patterns of its receptors, VEGF-C is likely to play a dual role both as an angiogenic
and lymphangiogenic growth factor.
VEGF-C potently induces an elongated, spindle-like cell shape change, and actin reorganization in both
VEGFR-2 and VEGFR-3 overexpressing endothelial cells (Cao et al., 1998). In the same study both
VEGFR-2 and VEGFR-3 mediate proliferative and chemotactic responses in endothelial cells upon VEGF-
C stimulation. It is likely that VEGF-C but not VEGF also serves in vivo as a natural chemoattractant for
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lymphangiogenesis, since it is capable of inducing the migration of VEGFR-3-overexpressing endothelial
cells (Cao et al., 1998).
4.5. VEGF-D
Structure and functional properties
VEGF-D is a 358-aa-long secreted protein. The VEGF-D gene was first identified as a c-fos-induced
growth factor (FIGF) (Orlandini et al., 1996). VEGF-D was cloned from mouse fibroblast and lung cDNA
libraries (Orlandini et al., 1996; Yamada et al., 1997; Achen et al., 1998; Rocchigiani et al., 1998). VEGF-D
and VEGF-C share 48% sequence identity and have similar N- and C-terminal extensions, a characteristic
which distinguishes them from the other members of the VEGF family. The VEGF homology domain of
VEGF-D is much more closely related to that found in VEGF-C than to those of the other family members.
The human VEGF-D gene spans about 50 kb and is organized into seven exons and six introns, its
promoter contains an AP-1-binding site but no TATA box (Rocchigiani et al., 1998). The human gene is
mapped to chromosomal region Xp22.1 (Rocchigiani et al., 1998; Yamada et al., 1997).
Receptor binding
The full length recombinant VEGF-D induces VEGFR-3 tyrosine autophosphorylation, whereas stronger
phosphorylation is obtained with a truncated derivative of VEGF-D, containing the VEGF homology domain
of VEGF-D corresponding to the so called mature VEGF-C. This shorter form of VEGF-D binds and
stimulates tyrosine phosphorylation of VEGFR-2 (Achen et al., 1998, 1999).
Expression
The expression of VEGF-D studied by in situ hybridization during mouse embryonic development is
detected in several parts of the body, such as limb buds, acoustic ganglia, developing tooth, heart, anterior
pituitary, lung, kidney mesenchyme, liver, skin, and periosteum of the vertebral column (Avantaggiato et
al., 1998). In mouse tissues two different transcripts of 2.4 and 3.7 kb are detected, with the highest
expression in the lung, and the weakest in the brain, spleen, and liver. In the kidneys and testes, additional
transcripts of 2.0 and 3.3 kb are observed (Yamada et al., 1997). In human adult tissues a 2.5-kb VEGF-D
mRNA is detected in lung and heart (Rocchigiani et al., 1998). In another study, high expression of a 2.2
kb VEGF-D transcript was reported in the human lung, heart and small intestine, and lower expression in
skeletal muscle, colon, and pancreas (Yamada et al., 1997). Expression in cancer cell lines is weak or
absent (Yamada et al., 1997).
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Biological activity and role
VEGF-D is capable of inducing mitogenic activity in fibroblasts, and also morphological alterations, but the
receptors responsible for mediating these effects have not been identified (Orlandini et al., 1996). It is of
interest to determine whether the cultured fibroblasts used for these studies expressed VEGFR-2 or
VEGFR-3. For example, the intracellular domain of VEGFR-3 is shown to be capable of stimulating
mitogenesis in fibroblasts (Pajusola et al., 1994; Borg et al., 1995). VEGF-D is a mitogen also for
microvascular and BAE cells but is about fivefold less potent than VEGF164 (Achen et al., 1998; Orlandini
et al., 1996). VEGF-D differs from the other members of the VEGF family because it is the only one
regulated by the nuclear oncogene c-fos (Orlandini et al., 1996). Furthermore, treatment of HUVECs with
VEGF-D induces a dose-dependent cell growth, elongation, branching and a formation of an extensive
network of capillary-like cords in a three-dimensional matrix (Marconcini et al., 1999). In an immortal cell
line derived from Kaposi's sarcoma lesion VEGF-D treatment results in dose-dependent mitogenic and
motogenic activities (Marconcini et al., 1999). VEGF-D is also a potent angiogenic factor in rabbit cornea in
vivo in a dose-dependent manner (Marconcini et al., 1999).
4.6. VEGF-E
Structure and properties
The genome of three strains of the Orf (OV) virus, NZ2, NZ7 and D1701, encodes polypeptides with
significant homology to the VEGFs (Lyttle et al., 1994; Meyer et al., 1999). The viral homologues are
collectively called VEGF-E, and they have the characteristic cysteine knot motif present in all mammalian
VEGFs. OV is a linear double-stranded DNA virus and a member of the parapoxvirus genus of the
Poxvirus family. It causes contagious pustular dermatitis in sheep and goats and occasionally is
transmissible to humans. The lesions induced by OV infection show extensive proliferation of the vascular
endothelium and blood vessel dilation. These responses are likely to be direct effects of the VEGF-like
gene. VEGF-E was expressed as the native protein in mammalian cells or as a recombinant protein in
Escherichia coli and found to act as a heat-stable, secreted dimer (Meyer et al., 1999). VEGF-E has 25%
amino acid identity with mammalian VEGF and is a dimer of approximately 44 kDa with no basic domain
nor affinity for heparin (Ogawa et al., 1998).
Receptor binding and signal transduction
VEGF-E binds VEGFR-2, resulting in receptor autophosphorylation and a biphasic rise in free intracellular
Ca2+ (Ogawa et al., 1998). Only VEGF-ENZ2 binds also to NP-1 (Wise et al., 1999). Another study reports
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the tyrosine phosphorylation of PLC-γ followed by activation of MAPK, upon induction of VEGF-E (Ogawa
et al., 1998).
Biological activity and role
VEGF-E is mitogenic for vascular endothelial cells in vitro and stimulates their chemotactic migration in in
vitro angiogenesis assays (Meyer et al., 1999). It also stimulates angiogenesis in vivo, induces new vessel
sprouts from pre-existing capillaries in a concentration-dependent manner, and sustains their growth and
elongation over time (Meyer et al., 1999). Additionally, VEGF-E induces potent in vivo angiogenic activity in
nude mice after subcutaneous Matrigel implantation and is also capable of increasing vascular
permeability (Ogawa et al., 1998). Furthermore, VEGF-E promotes neovascularization in rabbit avascular
cornea more efficiently than VEGF (Meyer et al., 1999). The angiogenic response appears to be direct as
no macroscopic signs of inflammatory reaction are detected (Meyer et al., 1999). VEGF-E induces also an
elongated morphology and tissue factor (TF) release in rat sinusoidal endothelial cells (Ogawa et al., 1998;
Meyer et al., 1999).
5.1. Tie receptors
Structure and chromosomal localization
Tie-1 and Tie-2 or (Tek) constitute another family of angiogenic endothelial cell surface receptor tyrosine
kinases. The human Tie-1 cDNA was isolated from erythroleukemia cells (Partanen et al., 1990; Partanen
et al., 1992). The mouse, rat, and bovine homologues were also isolated (Korhonen et al., 1992; Korhonen
et al., 1994; Maisonpierre et al., 1993; Sato et al., 1993). The Tie-1 gene is located in chromosomal region
1p33 to 1p34 in humans and in mice it is located on chromosome 4 (Partanen et al., 1992; Laan et al.,
1995; Sato et al., 1993). Tie-2, a closely related gene was cloned from different sources i.e. murine
embryonic heart, ES cells, brain capillaries, lung and yolk sac libraries (Dumont et al., 1992; Horita et al.,
1992; Iwama et al., 1993; Runting et al., 1993; Sato et al., 1993; Schnurch and Risau, 1993). In the mouse
Tie-2 is located on chromosome 4, in a region syntenic to human chromosome regions 1p22-23, 9q31-33
and 9p22-13 (Dumont et al., 1992; Sato et al., 1993). Tie-1 and Tie-2 encode 117 kDa and 140-kDa
polypeptides, respectively (Dumont et al., 1993; Partanen et al., 1992). Both Tie-1 and Tie-2 are receptors
with high sequence conservation in the cytoplasmic region, and difference in the extracellular ligand
binding region. Overall aa identity is 46%, with the highest identity, 84% occuring in TK1 and TK2 domains.
The extracellular region is composed of three distinct structural motifs that distinguish these receptors from
other RTKs. The extracellular region consists of a cluster of three epidermal growth factor homology motifs
positioned between one complete and one incomplete immunoglobulin-homology (Ig) domain. The second
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Ig domain is followed by three domains that show homology to fibronectin type-III domains (Partanen and
Dumont, 1999). Their extracellular regions contain putative N-linked glycosylation sites followed by a single
hydrophobic transmembrane domain. The cytoplasmic region consists of a tyrosine kinase (TK) domain
split by a kinase insert (Sato et al., 1993).
Expression
Both Tie-1 and Tie-2 are expressed in the early embryonic vascular system and in maternal decidual
vascular endothelial cells, where the vasculature undergoes active angiogenesis. Tie-2, but not Tie-1, is
expressed in the extra-embryonic mesoderm of the amnion (Dumont et al., 1992). Tie-1 expression is
downregulated after the fetal period in endothelial cells of many organs, yet the expression of Tie-1 and
Tie-2 persists in quiescent adult endothelial cells (Dumont et al., 1992; Korhonen et al., 1994). Tie-1 is
induced during physiological and pathological neovascularization (Hatva et al., 1994; Kaipainen et al.,
1994; Korhonen et al., 1992), and Tie-2 is as well upregulated in angiogenic capillaries in breast cancer
(Peters et al., 1998) and in gliomas (Stratmann et al., 1998). In addition, Tie-1 mRNA and protein levels
are increased in endothelial cells of arteriovenous malformations (Hatva et al., 1996). Tie-2 tyrosyl
phosphorylation is detected in the normal vasculature, suggesting that this receptor has an active role in
the maintenance of blood vessels (Wong et al., 1997). In adults the 4.5 kb Tie-2 mRNA is observed at high
levels in the lung and heart (Dumont et al., 1993; Iwama et al., 1993), in the endocardium and the
leptomeninges (Dumont et al., 1992). In addition, Tie mRNA is visualized in the walls of medium and large
vessels (Partanen et al., 1992).
Tie-1 and Tie-2 are restricted mainly to endothelial cells and their precursors (Korhonen et al., 1994;
Dumont et al., 1995) but they are also expressed in hematopoietic progenitors and differentiating
megakaryoblasts (Iwama et al., 1993; Sato et al., 1993; Schnurch and Risau 1993; Kukk et al., 1997; Sato
et al., 1998). Tie-1 mRNA expression seems to correlate with the differentiation stage of blood cells, being
highest in hematopoietic precursor cells, whereas the level is downregulated upon erythroid differentiation
(Iwama et al., 1993). The highest levels of Tie-1 mRNA expression in mouse cell lines is found in the 32D
and DA-3 cells, which are multipotent myeloid stem cells (Armstrong et al., 1993).
A 4.4-kb Tie-1 mRNA is detected in HEL cells, KG-1 myeloid leukemia cells, and Dami megakaryoblastic
leukemia cells. Tie-1 mRNA is expressed in endothelial cell lines, such as PAE cells and EA.hy926 a
hybrid of human endothelial and lung carcinoma cells (Partanen et al., 1992). Human solid tumor cell lines,
such as HT-1080 and 8387 fibrosarcoma as well as one melanoma cell line also expressed Tie mRNA
(Armstrong et al., 1993).
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Signal transduction
Tie-2 has two ligands, Ang-1 and Ang-2  which bind to it with similar affinity, but neither binds to the related
receptor Tie-1 (Davis et al., 1996; Maisonpierre et al., 1997). Ang-1 induces autophosphorylation of Tie-2
in cultured endothelial cells (Davis et al., 1996), whereas Ang-2 does not induce receptor phosphorylation
(Maisonpierre et al., 1997). In 3T3 fibroblasts ectopically expressing Tie-2 both Ang-1 and Ang-2 induce
receptor phosphorylation (Maisonpierre et al., 1997). SHP-2 and the adapter GRB2 are Tie-2 downstream
substrates (Huang et al., 1995).
Biological effects
Gene inactivation studies reveal the important role played by Tie-1 and Tie-2 during the later stages of
vascular development. Both receptors are required in the microvasculature during late organogenesis and
in essentially all blood vessels of the adult (Puri et al., 1999). Tie-2 is involved in establishing the correct
vascular patterning, whereas Tie-1 plays a role in maintaining vessel integrity, and preventing hemorrhage.
Tie-1 also funtions selectively in various capillary plexuses, for postnatal survival of endothelial cells (Suri
and Yancopoulos, 1998; Partanen and Dumont, 1999). Mouse embryos homozygous for a Tie-2-null allele
or expressing a dominant negative Tie-2 receptor die around E9.5. These mice display defects in the
vascular endothelium of the yolk sac, heart, dorsal aorta and microvasculature (Dumont et al., 1994; Sato
et al., 1995). The number of endothelial cells is decreased suggesting a role for Tie-2 in the expansion of
this lineage (Dumont et al., 1994). Hemorrhage in the mice is evident in parallel with an underdeveloped
heart. Incomplete sprouting and remodeling in addition to vasodilatation characterize the head region of
the mice and the yolk sac vessels (Sato et al., 1995). Embryos deficient in Tie-1 fail to establish structural
integrity of vascular endothelial cells, resulting to edema and hemorrhage (Sato et al., 1995; Puri et al.,
1995). Homozygous Tie-1 mutant mice die between E13.5 and one day after birth (Puri et al., 1995; Sato
et al., 1995). Tie-1 is not required for angioblast differentiation but it is needed during organogenesis to
promote angiogenic capillary growth (Partanen et al., 1996). Vasculogenesis proceeds normally in
embryos lacking both Tie-1 and Tie-2. Tie-2 is essential for the differentiation of the heart endocardium,
whereas Tie-2 and Tie-1 are dispensable for the initial assemply of the rest of the vasculature (Puri et al.,
1999). Both, Tie-2 and Tie-1 play essential functions in maintaining the integrity of the mature vasculature
(Puri et al., 1999).
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5.2. Angiopoietins
Structure and properties
Besides the VEGFs, angiopoietins are the only other known growth factors specific to the vascular
endothelial cells. The angiopoietin family includes the naturally occurring agonist, Ang-1 (Davis et al.,
1996), and the antagonist, Ang-2 (Maisonpierre et al., 1997).  Ang-1 gene encodes 498 amino acid
residues, including an amino-terminal secretory signal sequence (Davis et al., 1996). The Ang-2 gene
encodes a protein of 496 amino acid residues, with a secretion signal peptide. Ang-2 and Ang-1 are 60%
identical (Maisonpierre et al., 1997). More recently two new members have been described, angiopoietin-3
(Ang-3) in mouse which acts as an antagonist and angiopoietin-4 (Ang-4) in humans,  functioning as an
agonist (Valenzuela et al., 1999). Although Ang-3 and Ang-4 are structurally more diverged from each
other than are the mouse and human versions of Ang-1 and Ang-2, they apparently represent the mouse
and human counterparts of the same gene locus (Valenzuela et al., 1999).
Receptor binding
Ang-1 binds and induces the tyrosine phosphorylation of Tie-2 (Davis et al., 1996). Ang-2 binds but does
not activate Tie-2 and thereby is able to block Ang-1 activity in endothelial cells (Maisonpierre et al., 1997).
In NIH3T3 cells ectopically expressing Tie-2 receptors, Ang-2 is equivalent to Ang-1 in inducing the
phosphorylation of the receptor (Maisonpierre et al., 1997). It seems then, that Ang-2 acts as an antagonist
for Tie-2 in the context of the endothelial cells, but not in other cell types (Maisonpierre et al., 1997). Ang-4
and Ang-3 bind Tie-2 but only Ang-4 induces phosphorylation of Tie-2 (Valenzuela et al., 1999).
Expression
Early in mouse development, Ang-1 is found to be most prominent in the heart myocardium surrounding
the endocardium (Suri et al., 1996). Later in development, as observed in rat embryos, Ang-1 becomes
more widely distributed especially in the mesenchyme surrounding developing vessels and in close
association with endothelial cells (Davis et al., 1996). Ang-2 is not detected in the heart, but is abundant in
the dorsal aorta and its major branches and specifically in the smooth muscle layer (Maisonpierre et al.,
1997). In fetal liver, Ang-2 is not present in all vascular structures but is detected in cells at, or close to, the
lumen of hepatic vessels, in cells which are probably endothelial cells or pericytes (Hirschi and D´Amore,
1996). In adult human tissues, Ang-2 is detectable only in ovary, placenta, and uterus, which are the three
predominant sites of vascular remodeling in the normal adult. Ang-1 is widely expressed although in small
amounts in the heart and liver (Maisonpierre et al., 1997). Ang-1 mRNA is found in tumor cells and Ang-2
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mRNA is observed in the endothelial cells of a subset of glioblastoma blood vessels. Strong expression of
Ang-2 originates from small capillaries with few periendothelial support cells, whereas larger glioblastoma
vessels with the same characteristics show little or no expression (Stratmann et al., 1998). Ang-3 mRNA is
expressed in multiple mouse tissues whereas Ang-4 transcripts are noted in high levels only in human lung
(Valenzuela et al., 1999).
Biological activity and role
The embryonic expression profile of Ang-1, implies that it plays an important role in the heart during early
development, and an increasingly widespread role as the rest of the vasculature matures (Davis et al.,
1996; Suri et al., 1996). Ang-1 activation of Tie-2 does not induce the typical growth responses seen with
other endothelial growth factors (Davis et al., 1996). Ang-1 seems to play a crucial role in mediating
reciprocal interactions between the endothelium and surrounding matrix and mesenchyme. Thus Ang-1
may have a role in the maintenance of normal vasculature and Tie-2 activity (Peters et al., 1998). In
contrast, it has been suggested that local production of Ang-2 promotes angiogenesis in the presence of
VEGF, by inhibition of the stabilizing effect of Ang-1 and the subsequent loosening of the contacts
between endothelial and periendothelial cells (Hanahan, 1997). The disruption of the Ang-1 gene leads to
distinctive defects in embryonic vascular development, similar although more subtle to those seen in
embryos lacking Tie-2. At E9.5 Ang-1 deficient mice have an immature endocardium devoid of trabeculae
and loosely associated with the myocardium. A much less complex vascular network is formed composed
of an immature primary capillary plexus with dilated vessels that surround the developing forebrain.
Remodeling deficit is evident at E11.5 in the yolk sac and in the embryo resulting in a reduced number of
large vessels. The endothelial cells in these mutant mice are aberrantly rounded and poorly associated
with periendothelial cells and matrix. Mouse embryos homozygous for Ang-1 gene disruption, appear
abnormal by E11 and die by E12.5 (Suri et al., 1996). The phenotype of the mutant mice stands as an
evidence for the important role that Ang-1 plays in the development of the vasculature. In adult mice and
humans, Ang-2 is expressed only at sites of vascular remodeling, and transgenic overexpression of Ang-2
in vascular structures results in disrupted blood vessels (Maisonpierre et al., 1997). In conclusion, the Angs
and Tie-2 do not participate in vasculogenesis, but do play an important role in angiogenesis, vessel
remodeling and maturation (Dumont et al., 1994; Sato et al., 1995).
6. Ephrins and Eph-receptors
The Eph receptors comprise the largest subfamily or RTKs. The ephrins and their Eph receptors have
been mostly studied for their roles in the nervous system. They seem to help guide axons by mediating
repulsive cues (Flanagan and Vanderhaeghen, 1998). More recently the interest has been shifted to the
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role that ephrins and their receptors play in the development of arteries and veins. Arterial and venous
endothelial cells are distinct from the earliest stages of angiogenesis. The molecular determinants that
distinguish them include the transmembrane ligand, ephrin-B2 (Bennett et al., 1995; Bergemann et al.,
1995) and its receptor Eph-B4 (Andres et al., 1994). Ephrin-B2 is expressed on arterial endothelial cells
whereas Eph-B4 marks the venous endothelium (Wang et al., 1998). Because both, ephrin-B2 and Eph-B4
are membrane bound, signalling must occur at sites of cell-cell contact. The interactions between arterial
and venous endothelial cells are essential for the morphogenesis of the capillary network (Wang et al.,
1998).
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AIMS OF THE STUDY
The vascular endothelial growth factor family has been expanded by the isolation of four new members
sharing structural similarities with VEGF and PlGF. These factors are VEGF-B, VEGF-C, VEGF-D and
VEGF-E. They exert their biological effects by binding to endothelial cell specific high-affinity receptors
of the tyrosine kinase family, the VEGFRs. VEGF is regarded as the major inducer of angiogenesis in
both normal and pathological conditions, being potent in stimulating the proliferation, migration and
tube formation of endothelial cells, as well as regulation of vascular permeability. Due to their
homology with VEGF these newly cloned VEGFs are expected to function as regulators of the
endothelium. To gain further understanding of the overlapping or distinct roles they may share with
VEGF, we have undertaken the task of determining their expression patterns, and their specific
receptor binding on tissue sections during development, in certain adult tissues and in a variety of
tumors. The following studies were therefore undertaken:
- Characterization of the role of VEGF-C in vivo. Cloning of mouse VEGF-C and characterization of its
expression pattern during mouse embryonic development. Analysis of the in vivo distribution of VEGF-
C mRNA compared to its receptor VEGFR-3, in order to find out whether the action of VEGF-C could
be primarily via this receptor.
- Clarification of VEGF-B function in vivo, by analysis of its mRNA expression in relation to those of its
receptor VEGFR-1, during embryonic development.
- Determination of the binding sites of VEGF-C and VEGF in adult human skin, heart and lymph nodes
as well as in developing mouse embryos. Analysis of mRNA expression profiles of the specific
receptors for these factors and in parallel, comparison of the profiles with the binding patterns for the
factors.
- Examination of VEGF-B and VEGF-C expression, and their possible involvement in tumor associated
angiogenesis or/and lymphangiogenesis. A study to localize and quantify the mRNA and protein product
concentration of these two factors. This was to be carried out in a variety of tumors, since their expression
could suggest their contribution to tumor growth, in a similar way to VEGF.
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MATERIALS AND METHODS
LIBRARY DESCRIPTION SOURCE USED IN
12 day p.c Exlox
mouse embryo
cDNA Novagen I
Adult mouse heart
λZAP II
cDNA Stratagene I
Mouse heart –5’-
stretch-plus
cDNA Clontech I
CDNA PLASMID cDNA SOURCE NUCLEOTIDES
(bp)
USED IN
hVEGFR-1 pCR2.1-TOPO Dr E. Korpelainen 1438-2090 V
hVEGFR-2 pBS K II SK+ Dr A. Kaipainen 6-715 III
mVEGFR-2 pGEM 3Z(f+) Dr J. Rossant 1958-2682 V
hVEGFR-3 pGEM 3Z(f+) Dr A. Kaipainen 55-207 III
hVEGFR-3 pGEM 3Z(f+) Dr K. Pajusola 1-595 I
mVEGFR-3 pGEM 3Z(f+) Dr A. Kaipainen 1-192 I, V
mNP-1 pCR2.1-TOPO  A. Lymboussaki 1774-2936 V
hVEGF pGEM 3Z(f+) Dr D. Connolly 57-639 II
hVEGF-B pREP7 Dr B. Olofsson 1-382 II
mVEGF-B pREP7 Dr B. Olofsson 440bps (Sal-SacI
frag)
IV
hVEGF-C pREP7 Dr V. Joukov 495-1661 I, II
hVEGF-C pREP7 Dr V. Joukov 57-638 II
hVEGF-C pCRII Dr V. Joukov 287-696 II
mVEGF-C pBS K II SK+ Dr S. Taira 558-979 I
mVEGF-C pBS K II SK+ Dr S. Taira 499-656 I
mVEGF-D pBS K II SK+ A. Lymboussaki 394-864 unpublished
mVEGF-D pBS K II SK+ A. Lymboussaki 80-448 unpublished
NORTHERN BLOT DESCRIPTION SOURCE USED IN
7, 11, 15 and 17 day
postcoital mouse
embryos
Multiple tissue
mRNAs
Clontech I
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CELL LINE DESCRIPTION SOURCE OR
REFERENCE
USED IN
NIH3T3 Fibroblast, mouse Pajusola et al., 1994 I, V
PAE Endothelial, porcine Waltenberger et al.,
1994
I, V
BOSC 23 293 human embryonic
kidney, retroviral
ecotropic packaging
cell line
Pear et al., 1994 I
ANTIBODIES SOURCE OR REFERENCE USED IN
hVEGFR-2, polyclonal Waltenberger et al., 1994 I
hVEGFR-2, polyclonal Santa Cruz I
hVEGFR-3, polyclonal Dr K. Pajusola I
hVEGFR-3, monoclonal Dr A. Kaipainen III
hVEGF-B, polyclonal Olofsson et al., 1996a II, IV
mVEGF-B186, polyclonal Olofsson et al., 1996b II, IV
hVEGF-C, polyclonal Dr V. Joukov I
CD31, monoclonal DAKO III
PAL-E, monoclonal Sanbio, Uden III
laminin, monoclonal Sigma Chemical Co. III
Von Willebrand factor/factor
VIII-related antigen,
monoclonal
DAKO III
Phosphotyrosine, monoclonal Zymed; Transduction
Laboratories
I
GROWTH FACTORS SOURCE OR REFERENCE USED IN
rhVEGF165 R & D Systems III, V
VEGF-C 21-kd Joukov et al., 1997 III, V
Abbreviations: h, human; m, mouse; rh, recombinant human
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METHODS USED IN
Immunohistochemistry II, III, IV
mRNA in situ hybridization I, II, III, IV, V
Cell culture I, V
Cell transfection by calcium phosphate precipitation I
Screening of bacteriophage λ libraries I
DNA cloning and sequence analysis I
PCR IV, V
RT-PCR IV
Total RNA isolation IV
Northern hybridization I
Metabolic labeling I
Immunoprecipitation I
Western blotting I, IV
Receptor binding and competition assays I, III, V
mRNA isolation and Northern blotting II
Preparation of mouse tissues I, IV, V
Preparation of human fetal tissue (study protocol was
approved by Ethics committee of the hospital)
III
Protein radioiodination III, V
Protein expression in Baculovirus system IV
Preparation of antisera IV
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RESULTS AND DISCUSSION
VEGF-B expression during mouse embryonic development (IV)
With the isolation of the VEGF-related factors VEGF-B and VEGF-C we wanted to characterize their
expression profiles during embryonic development in order to define any possible overlapping and/or
distinct roles during vascular development. As judged from the spatiotemporal expression patterns of
VEGF-B and VEGF-C the growth factors may serve specialized functions in the development of different
kinds of vessels. The proper formation of the embryonic vasculature requires signaling by many factors
and possibly combined action of growth factors, which induce synergistic signaling events. The individual
ligand-receptor pairs may also contribute to different maturation states of specialized vessels needed for a
variety of tissues with unique metabolic demands.
The localization of VEGF-B during mouse embryonic development was examined thoroughly in this work,
with the aim of giving a deeper insight into the relationship between VEGF-B expressing cells and the
vasculature in developing embryos (IV). Previous studies have reported data on VEGF-B expression at
some stages of development (Lagercrantz et al., 1998; Lagercrantz et al., 1996; Olofsson et al., 1996a).
We used in situ hybridization and immunohistochemistry to better localize the distribution of VEGF-B
mRNA and protein in specific tissues and cells, and compared sites of expression using these two
methods (IV). RT-PCR analysis of VEGF-B and VEGFR-1 transcripts was carried out during
developmental stages E9, E11, E13 and E15. The results revealed that both major splice isoforms of
VEGF-B were expressed. In addition, we showed that in the same tissues both VEGFR-1 isoforms were
expressed, encoding the membrane bound and the soluble forms of the receptor (IV).
Mouse embryos were analyzed from E8.5 to E16.5 by in situ hybridization and from days E10.5 to E17.5
by immunohistochemistry. Transcripts for VEGF-B were observed at E8.5 in the developing heart and
head mesenchyme. Strong extra-embryonal signals originated from the allantois, the amnion and some
cells surrounding the venous lacunae of the developing placenta. Thus, VEGF-B may be involved in
promoting the formation of the allantoic vasculature which occurs intrinsically by vasculogenesis rather
than extrinsically via angiogenesis from the adjacent yolk sac or fetus (Downs et al., 1998). The strong
expression of VEGF-B in the heart continues throughout the gestation. It was possible to see in the E9.5-
E11.5 embryos the signal originating from the developing cardiac myocytes, whereas the atrio-ventricular
septal region was negative. Beginning at E12.5 the outer layers of the anterior and posterior choroid
plexus exhibited signals, coinciding with the period of the development of this structure. Expression was
found in the nasopharyngeal area, around the vertebral corpuscles, the metanephric area, the Purkinje
cells of the cerebellum, the lung and strongly in the diaphragm. The expression patterns did not differ
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during E13.5-E14.5, whereas on E15.5-E16.5 an intense signal was detected from many muscle
derivatives.
Abundant VEGF-B mRNA and protein were consistently observed in the developing heart, many skeletal
muscles and smooth muscle cells of the larger vessels. Quantitative and qualitative differences occured
between the expression levels of VEGF-B transcript and protein. The reasons underlying these differences
are not clear, but they may be linked to tissue-specific differences in mRNA or protein stabilities or to the
presence of VEGF-B binding proteins in muscle tissue. VEGF-B protein staining was observed from E12.5
in the smooth muscle cells of the larger vessels, such as in scattered cells of the aorta, the carotid artery
and the subclavian artery. At E14.5 VEGF-B appeared in the vascular smooth muscle cells of the
intervertebral and lung vessels, and in the kidney arteries at E15.5. Later on, at E17.5, staining was found
in the arterial smooth muscle cells of brown fat and of the intestine. The sequential appearance of VEGF-B
immunoreactivity in the different vessels was consistent with the spatial and temporal pattern of smooth
muscle cell differentiation, as previously noted (Takahashi et al., 1996). VEGF-B was expressed in the
developing skeletal muscles starting from E10.5. VEGF-B protein was detected at later stages in the
developing skeletal muscles, such as in the intersegmental muscles of the vertebrae and the muscles of
the extremities; the entire diaphragm became positive.
In addition, VEGF-B protein was detected in the developing bone and cartilage, brown fat, and in several
organs, including some exocrine and endocrine glands such as the pancreas and adrenal gland. The ribs,
vertebrae, and the long bones of the extremities were positive for VEGF-B starting from E14.5 onwards,
exactly when the endochondral ossification is known to start in the developing embryo, with a peak at
E15.5 and a decline at E17.5 (Caplan, 1988). Upon analysis, VEGF-B was found not to be expressed by
the cartilage, but rather by surrounding perichondrium, which provides a matrix for capillaries invading the
ossifying bone. This suggested a role for VEGF-B in angiogenesis of the bones and subsequent
ossification. Endochondral bone formation is a mechanism in which cartilage is replaced by bone. This
process is necessary for longitudinal bone growth during vertebrate development and requires the blood
vessel invasion of cartilage. During this process, at least VEGF mediates capillary invasion, which
regulates growth plate morphogenesis. VEGF is produced by hypertrophic chondrocytes, it recruits
endothelial cells and induces angiogenesis. VEGF inactivation results in a complete disruption of the
normal vascular pattern of the growth plate in juvenile mice (Gerber et al., 1999; Harper and Klagsbrun,
1999). Such angiogenic role for VEGF-B may not be valid in general. For example, the brain and lung,
which are vascularized by active angiogenesis, show VEGF-B expression only in the smooth muscle layers
of the large vessels.
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The intensively VEGF-B expressing tissues, heart, muscle, and brown fat all have a high capillary density,
and share common features such as a high metabolic turnover rate. VEGF-B may have an additional
effect, besides VEGF, on the angiogenic processes governing the extensive capillary ingrowth into these
tissues. VEGF-B may be involved in regulating the assembly of the growing vasculature, in addition to
growth regulation during angiogenesis, since the inactivation of its only reported receptor VEGFR-1 results
in well developed but unsuccessfully assembled endothelial lumens (Fong et al., 1995). However, the
recent report that inactivation of the VEGFR-1 TK domain has no in vivo phenotype (Hiratsuka et al., 1998)
suggests that intracellular signal transduction by activated VEGFR-1 plays no direct role in the organization
of the vasculature.
Targeting of the VEGF locus shows that VEGF-B or any other VEGF is unable to compensate for the loss
of even a single allele of VEGF, even though these growth factors have partially overlapping receptor
specificities. However, VEGF-B does not bind to or activate VEGFR-2, which is the receptor implicated in
the differentiation and proliferation of endothelial precursor cells, which form the embryo´s primary vascular
network. Furthermore, the difference between VEGF and VEGFR-2 deficient mice, suggests redundancy
of VEGF related factors during early development. The delayed endothelial cell differentiation in VEGF
deficiency is different from the aborted endothelial cell development in VEGFR-2 deficiency (Carmeliet et
al., 1996; Ferrara et al., 1996; Shalaby et al., 1995).
Based on the localization of VEGF-B, it might be expected that targeted inactivation of the VEGF-B gene
would result in a phenotypic change in tissues which highly express this factor, such as the heart and
skeletal or arterial muscles. On the other hand, since two other growth factors, PlGF and VEGF, share a
receptor with VEGF-B, it is possible that they could compensate for the defects caused, which would result
in a mild phenotype for the mutant mice. At least PlGF is not expressed during embryonic development
except extra-embryonally in the villous trophoblasts of the placenta (Persico et al., 1999; Vuorela et al.,
1997). Thus, it is unlikely that PlGF would compensate for the loss of VEGF-B expression.
VEGF-B forms disulfide-linked heterodimers with VEGF when co-expressed in the same cells (Olofsson et
al., 1996a; Olofsson et al., 1996b). Co-expression of these two factors occurs in many embryonic tissues,
so the formation of heterodimers is also likely to occur, and this of course is of interest because of their
shared receptor specificity (de Vries et al., 1992; Millauer et al., 1993; Olofsson et al., 1998; Terman et al.,
1992). VEGF is expressed during embryonic development in the myocardium, neural ectoderm, head
mesenchyme, and gut endoderm. The expression patterns of VEGF and VEGF-B partially overlap in the
heart myocytes, the choroid plexus epithelium, the head mesenchyme and the neural ectoderm (Breier et
al., 1995; Dumont et al., 1995 and IV). The common receptor VEGFR-1 is as well expressed in the choroid
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plexus and the neuroectoderm as well as in most blood vessels and capillaries throughout development
(Breier et al., 1995).
VEGF and more recently the Angs are shown to be expressed in perivascular cells, such as pericytes and
vascular smooth muscle cells. Paracrine signaling between endothelial and perivascular cells appears to
be vital for the development of the vasculature, and for the maintenance of the normal features and
stability of the vascular tree (Benjamin et al., 1998). Based on its localization as shown in our studies,
VEGF-B is likely to act in a paracrine fashion, from the VEGF-B expressing perivascular cells to adjacent
endothelial cells expressing its receptor VEGFR-1 (IV). Interestingly, one report claims that VEGFR-1 is
expressed in pericytes (Nomura et al., 1995). If this is the case, VEGF-B could also possibly act in an
autocrine manner. According to our mRNA and protein localization studies, VEGF-B may have a function
in the vascularization of the heart, skeletal muscles and developing bones, and also in the paracrine
interactions between the endothelial and surrounding smooth muscle cells (IV). VEGF-B binding to
VEGFR-1 could also have a function in the regulation of blood vessel physiology in adults.
Cloning and analysis of mouse VEGF-C cDNA (I)
The analysis of the cloned mouse VEGF-C cDNA showed that the open reading frame encodes a
polypeptide of 415 amino acid residues (I). This study demonstrated a conservation of the primary
structure between mouse and human VEGF-C. A hydrophobic sequence of 31 amino acid residues,
fulfilling the criteria for a secretory signal sequence, was located on the N-terminus. By analogy with the
human sequence, the mouse VEGF-C mRNA 3´of the segment encoding the signal sequence should
encode the N-terminal propeptide. This N-terminal propeptide differed from the human homologue by an
apparent deletion of four amino acid residues corresponding to the human amino acids H88-E91. The
overall homology between the mouse and human prepro-VEGF-C open reading frames was 85%. The
VEGF-homologous region was 94% identical between the mouse and human VEGF-C; the
carboxyterminal region was 85% and the N-terminal propeptide 79% identical.
VEGF-C receptor binding (I)
Mouse VEGF-C bound and stimulated the autophosphorylation of human VEGFR-3 to a similar extent as
human VEGF-C (I). These binding studies were performed with media from BOSC23 cells transfected with
mouse VEGF-C cDNA expression vector. This mouse VEGF-C containing culture medium stimulated the
autophosphorylation of VEGFR-3 polypeptides to a similar extent as human baculoviral VEGF-C. VEGFR-
2 is prominently phosphorylated in response to baculoviral VEGF-C, whereas tenfold concentrated medium
containing human and mouse recombinant VEGF-C gave a weak and barely detectable enhancement of
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autophosphorylation (I). It is demonstrated that in human VEGF-C only the mature fully processed form of
21 kDa is a high affinity ligand and an activator of both VEGFR-3 and VEGFR-2, whereas the non-
processed and partially processed VEGF-C forms preferentially bind to and activate VEGFR-3 (Joukov et
al., 1997).
Antibodies generated against a 17 amino acid peptide of the N terminus of human VEGF-C recognized
mouse VEGF-C. Expression of recombinant mouse VEGF-C from a retroviral DNA construct gave rise to
secreted polypeptides of 30-32 kDa and 22-23 kDa forms that were capable of binding to the human
VEGFR-3 receptor. This established a cross-species interaction, which could be useful in generating viral
vectors, transgenic mice and production of recombinant human factor and their testing in experimental
animals.
The concentrations of VEGF factors may be critical for the specificity of their biological effects, as is
suggested by the gene targeting studies performed on VEGF, where there appears to be a delicate ligand
dose dependence on the effect of this factor (Carmeliet et al., 1996). Since fairly high VEGF-C levels are
needed for activation of VEGFR-2, the significance of such an interaction requires further study. High
concentrations of VEGF-C could also occur in vivo and if so, this could depend upon special conditions
and factors such as stimulation of VEGF-C expression by angiogenic proinflammatory cytokines (Ristimäki
et al., 1998) or growth factors (Enholm et al., 1997).
VEGF-C expression during mouse embryonic development (I)
It was of interest in this work to determine whether the VEGF-C expression correlated with the expression
of its high affinity receptor VEGFR-3, which becomes restricted to lymphatics after the differentiation of the
vasculature (Kaipainen et al., 1995). This correlation would suggest that VEGF-C could be primarily a
VEGFR-3 ligand also in vivo. If VEGF-C is distributed widely this suggests also a role in embryonic
angiogenesis through VEGFR-2, since this receptor is detected in all the endothelia during development
(Millauer et al., 1993). By Northern blot analysis VEGF-C was found to be constantly expressed between
gestational ages E7-E17 (I). In adult mouse tissues, the heart and lung exhibited the strongest signals, and
comparison with VEGFR-3 expression revealed that tissues expressing VEGF-C also contained mRNA for
its receptor VEGFR-3. The commencement of VEGF-C expression on day 7 p.c. was striking considering
the appearance of VEGFR-3 mRNA first on day 8.5 of gestation (Kaipainen et al., 1995). However, it is
likely that some of the VEGF-C mRNA detected by Northern blots was actually derived from maternal
tissue, where VEGF-C was also expressed, according to in situ hybridizations performed for this study. In
situ hybridization experiments were not performed for days earlier than 8.5, so we can not be sure of the
intra-embryonic expression of VEGF-C at the very early developmental time points. These results suggest
that VEGF-C interacts with VEGFR-2 during early development, since no other known receptors are
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available at this time (Yamaguchi et al., 1993). Thus, depending on the relative concentration of VEGF-C,
it could contribute to angiogenic signal transduction via VEGFR-2 in very early embryos. It should also be
noted that the comparison of the VEGF and VEGFR-2 knockout phenotypes suggests that there may be
yet another ligand for VEGFR-2 (Carmeliet et al., 1996; Ferrara et al., 1996; Shalaby et al., 1995).
VEGF-C mRNA distribution on days 8.5-16.5 of mouse embryonic development was analyzed by in situ
hybridization. VEGF-C mRNA at E8.5 localized to the head mesenchyme, whereas VEGFR-3 was
localized to the angioblasts in the same region. Extra-embryonally, both VEGF-C and VEGFR-3 were
observed in the allantois. Interestingly, although VEGFR-3 transcripts were distributed abundantly in the
endothelium of the venous lacunae of the placenta, the surrounding cells were found to be devoid of
transcripts for VEGF-C, which bound to this receptor (I). At E9.0, VEGF-C transcripts were present in
mesodermally derived cells of the aortal region and of the yolk sac, whereas VEGFR-3 was expressed as
indicated by β-Gal staining, in the endothelial cells of the dorsal aorta and the yolk sac (Dumont et al.,
1998). VEGF-C mRNA was expressed in adjacent areas when compared with the distribution of its
receptor VEGFR-3. VEGF-C transcripts were particularly localized in the intervertebral spaces, whereas
VEGFR-3 was expressed in the intervertebral vessels (I). A VEGF-C signal was obtained from the
mesenchyme around large sac-like structures in the jugular area, and VEGFR-3 was found lining the
borders of these sacs. From the jugular area, the first lymphatic vessels sprout from venous sac-like
structures according to Sabin´s theory (Sabin, 1909). Thus, VEGFR-3 was apparently present in the
endothelial cells lining such vessels. VEGF-C was also found in the mesenterial connective tissue, where
VEGFR-3 decorated developing lymphatic vessels (I).
Our study suggested that VEGF-C could be a high affinity ligand primarily for VEGFR-3. The expression of
VEGF points out a role for it as a major regulator of overall angiogenesis in the embryo (Breier et al.,
1992), whereas VEGF-C is necessary for the early development of the cardiovascular system and seems
to function later on in the development and maintenance of the lymphatic system (Dumont et al., 1998;
Kaipainen et al., 1995 and I). A paracrine relationship is suggested for this ligand-receptor pair resulting
from the observation that VEGF-C was expressed in mesenchymal cells adjacent to VEGFR-3 positive
endothelia.
VEGF-D expression during mouse embryonic development (Unpublished results).
We also performed in situ hybridization analyses for VEGF-D, which is the closest relative of VEGF-C,
enabling a comparison of the sites of their biosynthesis and the similarities and differences in their tissue
distributions in relation to VEGFR-2 and VEGFR-3 (Athina Lymboussaki unpublished data; I, Millauer et al.,
1993; Kaipainen et al., 1995). Comparison of the expression patterns for these two related growth factors
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revealed overlapping signals in many tissues. The mRNAs of both growth factors were detected around
the developing metanephros and in the nasopharyngeal, jugular and neck areas in a manner
complementary to their receptor VEGFR-3 (I; Kaipainen et al., 1995 and Athina Lymboussaki unpublished
data). Both factors were also found in the mesenchyme of the anterior part of the developing vertebral
column, along the thoracic duct where VEGFR-3 is expressed (Kaipainen et al., 1995; Athina Lymboussaki
unpublished data; I). Furthermore, VEGF-D expression was distinct from VEGF-C and very strong in the
lung, the endocardial cushion tissue, the subcutaneous tissue, the adrenal gland, and the developing tooth
(Athina Lymboussaki unpublished data, see Figure 6). The recently published developmental expression
pattern of the murine FlGF which is identical to mouse VEGF-D (Avantaggiato et al., 1998), was found to
correlate well with our results. VEGF-C expression was downregulated after E12.5 in many tissues, while
VEGF-D was more faintly expressed than VEGF-C during very early development, the expression
increasing later on. This indicated that the two growth factors act during different developmental periods.
VEGF-C may play an important role during early embryogenesis and VEGF-D later on in development.
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Fig. 6. Localization of VEGF-D transcripts in mouse embryos analyzed by in situ hybridization. A. In the
E8.5 embryo, VEGF-D is expressed in the head mesenchyme (m), and in some cells surrounding the
venous lacunae (vl). C. E12.5 embryo showing VEGF-D expression in the endocardial cushion tissue of
the heart (h), the metanephric area (mn), the mesenterium (ms). E-L. Higher magnifications of regions
expressing abundant VEGF-D transcripts. E. High levels of transcripts are detected in the lung (lu) in the
E13.5 embryo (arrow). G Signal from the jugular area (j) in an E13.5 mouse embryo (arrow). I. In the E14.5
embryo, VEGF-D is detected in the mesenchyme in close proximity of the mesenterial vessels (arrow).
Blood cells gave a false positive signal (asterix). K. The linings of the adrenal gland (ad) and the kidney (k)
are strongly positive (arrow) at E15.5. B. D. F. H. J. L. Bright field microphotographs of the sections. C:
cartilage primordium, g: gut, cp: choroid plexus.
VEGF and VEGF-C binding to embryonic and adult endothelia (V).
Radioactive ligand binding experiments were performed in this study on tissue sections in order to
understand better the specific functions of VEGF and VEGF-C in vivo (V). Binding was analyzed in mouse
embryonic, as well as in adult tissue sections, and growth factor binding distribution was compared to the
expression patterns of the three known members of the VEGFR family as well as to NP-1, a coreceptor for
VEGF165. Partially overlapping patterns of VEGF and VEGF-C binding were obtained in embryonic tissues,
consistent with the expression of all known VEGF receptors by vascular endothelial cells (V).
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VEGF and VEGF-C binding to mouse E8.5 embryos (V).
The binding patterns of VEGF-C and VEGF were similar in the tissues of E8.5 embryos, but some
differences in the distribution of binding sites occured extra-embryonally. The binding profiles were in good
correlation with the localization of their specific receptor mRNAs. VEGF-C, but not VEGF, bound to the
giant cells partially fused to the Reichert´s membrane, where VEGFR-3 and VEGFR-2 are expressed,
while VEGFR-1 was not detected in this area. In contrast, binding of VEGF but not VEGF-C was detected
in the amnion, perhaps explained by the presence of VEGFR-1, VEGFR-2 and NP-1, and absence of
VEGFR-3 (our unpublished data and Breier et al., 1995; Kaipainen et al., 1995). Some binding sites for
VEGF-C were found in the yolk sac, where VEGFR-1, VEGFR-2, VEGFR-3 and NP-1 were expressed (our
unpublished data). VEGF-C did not bind to the ectoplacental cone, whereas VEGF bound to its proximal
part where VEGFR-1 was expressed. Therefore, we hypothesized that at this developmental stage VEGF-
C bound to VEGFR-3, especially since the cross competition with VEGF did not change the VEGF-C
binding pattern, and that VEGF in these conditions bound predominantly to VEGFR-1. The extraembryonic
binding profile of VEGF to structures of VEGFR-1 expression, questioned the binding of this factor to
VEGFR-2 at this developmental stage.
VEGF and VEGF-C binding to mouse E12.5 embryos (V).
At E12.5 VEGF-C bound to the metanephric, the nasopharyngeal and jugular regions. Binding was also
observed in the intervertebral vessels, the subcutaneous vascular plexus and the capillaries of the brain
and neck. Binding furthermore occured in the main cerebral artery and the vessels of the corpus striatum,
which were shown in this study to express VEGFR-2 (V). VEGFR-3 and VEGFR-2 mRNAs are co-
expressed in many tissues, except that VEGFR-2 is more prominent in certain vessels, such as the
capillaries of the developing central nervous system and the heart (V and Kaipainen et al., 1995). In the
developing heart the epicardium contained abundant binding sites for VEGF-C, whereas the endocardium
which expressed VEGFR-1, VEGFR-2 and NP-1, but not VEGFR-3, did not give a VEGF-C binding signal.
Some additional binding of VEGF-C, which is not in accordance with VEGFR-3 mRNA localization at such
sites, occured in the heart, the capillary network of the brain, the corpus striatum and the spinal cord. This
outcome could be attributed to the presence of an as yet unknown receptor for VEGF-C, or to the binding
of VEGF-C to VEGFR-2. The developing mouse brain expresses small amounts of VEGFR-3 as well as
VEGFR-1 and VEGFR-2; this coincides with invading vascular sprouts (Breier et al., 1995; Kaipainen et al.,
1995; Millauer et al., 1993). The mature form of VEGF-C used in the binding experiments resembles the
shortest splice isoform of VEGF, namely VEGF121, which is reported not to bind NP-1.
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As VEGF is known to have a 5- to 10-fold higher affinity to VEGFR-1 than to VEGFR-2 (Quinn et al., 1993;
Waltenberger et al., 1994), binding at the concentrations used in our studies occurs probably preferentially
to VEGFR-1. However, the intense VEGF binding pattern observed in E12.5 embryos, especially in the
heart can not be fully explained by binding to VEGFR-1 only. It is possible that the strong VEGF binding to
cardiac myocytes is attributed to NP-1. In the mouse heart, NP-1 is expressed in the cardiac myocytes,
endocardial cells and in blood vessels; in the latter presumably in both endothelial and mesenchymal cells
(Kitsukawa et al., 1995). The fact that no significant changes in the VEGF binding pattern were obtained
upon cross competition with VEGF-C may be explained by the inability of VEGF-C to compete for binding
to VEGFR-1 and NP-1. Whether VEGF-C and VEGF also bind to VEGFR-2 in embryos, in addition to their
higher affinity receptors VEGFR-3 and VEGFR-1, respectively, is unclear. The partially overlapping binding
patterns of VEGF and VEGF-C may be explained either by co-expression of VEGFR-3 and VEGFR-1 in
the same cells or binding of VEGF-C to VEGFR-2.
The VEGF and VEGFR knockout experiments strongly suggest that VEGF is a ligand for VEGFR-2
(Carmeliet et al., 1996; Ferrara et al., 1996; Shalaby et al., 1995). VEGFR-2 appears to be the primary
receptor that mediates the mitogenic and chemotactic effects of VEGF on endothelial cells (Clauss et al.,
1996; Waltenberger et al., 1994). VEGFR-1 binds VEGF with high affinity but it has not been shown to
transmit a mitogenic signal, but may be involved in cell migration (Barleon et al., 1996). At least in the
binding of VEGF to the E8.5 embryo in our experiments occurs to VEGFR-1. This demonstrates a strong
biochemical interaction not necessarily emphasizing the biologically relevant interactions. VEGFR-1 signal
transduction does not seem to include the tyrosine kinase domain of the receptor since the disruption of
this domain by gene targeting does not affect normal embryonic development (Hiratsuka et al., 1998).
VEGFR-1 probably acts as a negative regulator binding excess VEGF and regulating the amount of
available VEGF for vascular development. Furthermore, the specific conditions under which our binding
experiments were performed on slides may not be achievable in vivo. Receptor sites may be available but
the amount of VEGF for binding in vivo may not be sufficient in all the tissues examined in our study.
VEGF and VEGF-C binding to mouse adult tissues (V).
Selective binding of VEGF-C occured to its lymphatic vascular receptor in certain adult tissues, whereas
VEGF bound to both of its receptors (V).  In the lymph nodes, VEGF and VEGF-C showed distinct binding
patterns in agreement with the differential location of their specific receptors. VEGF-C binding was
localized to the hilus and to the paracortex, a region occupied by T lymphocytes and rich in lymphatic
sinuses, which enter the lymph node. The lymphatic sinuses also gave an intense signal for VEGFR-3
mRNA. In contrast, VEGF bound to vessel structures in the medullar region. High endothelial venules,
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which are the main pathway for lymphocyte entry into the lymph nodes and extravasation into tissues, exist
mainly in the paracortical area of the lymph node and are positive for VEGFR-3 (Kaipainen et al., 1995).
The most striking differences of binding were observed in the heart, where VEGF decorated all vessels,
whereas strong VEGF-C signals were obtained only from epicardial vessels. Strong signals from the bound
VEGF-C were localized to irregular and collapsed pericardial vessels, and only weak signals were obtained
from the myocardial vessels. VEGFR-3 transcripts are present in the epicardial vessels, but very little
mRNA is detected in the myocardial capillaries (Kaipainen et al., 1993; Partanen et al., 1999a). It was thus
suggested that VEGF-C binds mainly to VEGFR-3 in the adult heart. Labeled VEGF, on the other hand,
bound to the endothelium of several types of vessels, and to a larger extent to the myocardial capillaries.
This suggested that VEGF bound to VEGFR-1 in the myocardial vessels, which express this receptor,
while both VEGF receptors could be binding targets in myocardial and epicardial capillaries, in which they
are coexpressed (Kaipainen et al., 1993; Partanen et al., 1999a). NP-1 could also provide VEGF binding
sites in the adult heart. In conclusion, it must be noted that these growth factors bound selectively to
endothelia adapted to serve specialized functions in the differentiated vessels of adult organs. The results
from our binding studies suggested that VEGF and VEGF-C have distinct binding profiles in adult tissues
where VEGFR-3 is largely confined to the lymphatic vasculature, to which VEGF-C binds preferentially (V).
This is in agreement with the lymphangiogenic effect of overexpression of VEGF-C in the basal layer of the
epidermis, indicating together with our results the in vivo specificity of this factor towards VEGFR-3 (Jeltsch
et al., 1997). The angiogenic effect of VEGF-C in vivo in the mouse cornea or rabbit hindlimb model is not
explained by the preferential binding to VEGFR-3 (Cao et al., 1998; Witzenbichler et al., 1998). Further
work is needed to clarify the mechanisms leading to the angiogenic vs. lymphangiogenic effects of VEGF-
C in such models. Although our results help to explain why VEGF and VEGF-C have overlapping and
distinct activities via their endothelial receptors, assessment of the binding sites and receptor expression
now needs to be carried out also in pathological conditions, such as in tissue ischemia.
VEGFR-3 mRNA and protein in lymphatic endothelium of the skin (III).
In our studies in the present thesis we applied VEGFR-3 as a specific antigenic marker for lymphatic
endothelial cells in the human skin and showed that it identified a distinct vessel population both in fetal
and adult skin, which had the properties of lymphatic vessels (III). To confirm the sites of VEGFR-3
expression in the skin, we performed in situ hybridization in order to localize its mRNA. Our studies
revealed the expression of VEGFR-3 mRNA to localize to putative developing lymphatic vessels, mainly in
the upper part of the developing dermis. The cells showing the VEGFR-3 signal were often devoid of
surrounding vessel wall structures; e.g., no basement membrane could be identified around these cells.
VEGFR-2 transcripts were located in numerous vessels at various levels of the dermis. These findings
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were in agreement with a previous report, where the distribution of these receptors in different fetal organs
partially overlaps, yet certain endothelia lack one or two of the VEGFRs (Kaipainen et al., 1993).
VEGF and VEGF-C binding in human adult skin (III).
In the skin, all the results that we obtained with iodinated ligand binding experiments were consistent with
the results obtained by in situ hybridization (III). In the human adult skin, radioiodinated VEGF-C bound
selectively to a subset of vessels that had the morphological characteristics of lymphatic vessels, whereas
VEGF bound to all discernible vessels throughout the dermis. Lymphatic vessels bound radioactive VEGF-
C in human adult skin specifically in a horizontal zone of the sub-papillary lymphatic plexus, which occurs
in association with the superficial venous system, at the junction of the papillary and reticular dermis.
Possibly being better developed in the adult skin, these vessels were viewed as long extended structures,
often collapsed, and had thin walls when compared with the thicker walls of nearby blood vessels. VEGF-C
binding was also detected in the lymphatic vessels of the deep dermal-subcutaneous junction. The
iodinated VEGF-C bound preferentially to the lymphatic vessels in which VEGFR-3 was shown to be
expressed by in situ hybridization (III). These results were in agreement with findings mentioned earlier
according to which VEGFR-3 expression becomes restricted to the lymphatic vessels in adult mouse
tissues and some HEVs in adult human tissues (Kaipainen et al., 1995). Surprisingly, although VEGF-C
and VEGF compete for VEGFR-2 binding, radio-iodinated VEGF-C binding to the skin was not decreased
by the addition of cold VEGF, suggesting that in this tissue sample, VEGF-C bound mostly to VEGFR-3.
This can not be fully explained by the threefold-greater affinity of VEGF-C toward VEGFR-3, when
compared with binding to VEGFR-2 (Joukov et al., 1997). Radio-iodinated VEGF bound to most of the
vessel structures, including those that bound radioactive VEGF-C. VEGF has about a 5- to 10-fold greater
affinity for VEGFR-1 than to VEGFR-2, so that the observed signal in this experiment could originate from
binding mostly to VEGFR-1 (Breier et al., 1995; Millauer et al., 1993; Peters et al., 1993; Quinn et al.,
1993). Specially, if VEGFR-1 is expressed in the same endothelia, blocking of VEGFR-2 sites with VEGF-
C would not necessarily change the binding patterns.
VEGFR-3 expression in vascular and other tumors (III).
Based on the above results, cutaneous lymphangiomatosis was chosen as the first pathological tissue for
immunohistochemistry, because it is a disorder characterized by proliferation of cells assumed to originate
from the lymphatic endothelium (Gometz et al., 1995). Whereas the dermal lymph vessels were relatively
weakly stained in healthy adult skin using anti-VEGFR-3, the endothelia of lymphangiomatosis lesions
were strongly stained (III). This is in agreement with earlier results showing enhanced VEGFR-3 mRNA
expression in lymphangiomas (Kaipainen et al., 1995). These results also supported the theory that the
lymphangiomatosis lesions do indeed develop from aberrant rests of lymphatic tissue with obliteration of
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draining lymphatics (Ramani and Shah, 1993). We also compared lymphangiomatosis staining with that of
capillary hemangioma, which is a benign acquired vascular tumor, consisting of multiple thick- and thin-
walled vascular structures (Wade et al., 1978). Compared with normal capillaries, the vessels in capillary
hemangiomas have a more prominent endothelial lining. The antibodies against VEGFR-3 gave little or no
staining in the blood vessel endothelium, but yielded weak staining of small vessels in intra-muscular
hemangiomas. The staining results indicated that these lesions contained endothelial cells in vessels that
share phenotypic properties with the lymphatic vessels. One possibility is that such vessels are less
differentiated than mature blood vessels, thus resembling early embryonic vessels, which express all three
VEGFRs (Breier et al., 1995; Kaipainen et al., 1995; Millauer et al., 1993; Peters et al., 1993).
In two separate studies not part of this thesis, the same antibodies against the VEGFR-3 extracellular
domain stain the endothelial cells of lymphatic vessels around tumors such as lymphoma and in situ breast
carcinoma (Jussila et al., 1998; Valtola et al., 1999). Additionally, tumor cells of several cutaneous nodular
AIDS-associated Kaposi´s sarcomas and the endothelium around these nodules are also VEGFR-3
positive (Jussila et al., 1998).
The mechanisms controlling the sprouting of new blood vessels from pre-existing ones, such as the VEGF-
VEGFR system, are of interest as targets for the therapeutic control of tumor angiogenesis (Folkman,
1995). Lymphangiogenesis, however, has not been reported in normal adult tissues or tumors (Folkman,
1996). Additionally the existence of lymphatics in tumors has been questioned. It is of interest as to
whether lymphangiogenesis occurs in some tumors, or whether solid tumors just compress nearby
lymphatic vessels which cannot penetrate into the tumor mass because of an elevated interstitial fluid
pressure (Jain, 1989). It is also of importance to explore whether tumor cells secrete VEGFs which would
induce increased growth of the nearby vessels. Our results suggest that VEGF-C and VEGFR-3 could be
components of a paracrine signaling network between tumor cells and the lymphatic and blood vascular
endothelium. Similarly, analysis of RNA isolated from various lymphoid organs reveal that lymph nodes are
a major site of VEGF-C gene expression, suggesting a paracrine mode of action for this factor and its
receptor (Jussila et al., 1998).
VEGF-B and VEGF-C expression in tumors (II).
It is well established that the growth of solid tumors is dependent on angiogenesis and VEGF is a secreted
endothelial-cell-specific mitogen. VEGF is hypoxia-inducible in vitro in a variety of cultured cells (Namiki et
al., 1995; Shweiki et al., 1992; Shweiki et al., 1995) and in vivo in a range of tissues (Banai et al., 1994;
Peér et al., 1995). Expression of VEGF increases tumor growth and angiogenesis in vivo in a nude mouse
model (Claffey et al., 1996; Ferrara et al., 1993; Zhang et al., 1995). It was of interest to characterize the
roles of the newly cloned endothelial growth factors VEGF-B and VEGF-C, which share structural
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homology with VEGF. The possible involvement of VEGF-B and VEGF-C in tumor angiogenesis in a
manner similar to VEGF was questioned. Therefore, their expression was examined in a variety of human
tumors, both malignant and benign (II).
VEGF-B mRNA was detected by Northern blot analysis in most of the tumor samples studied and it was,
together with its protein product, localized to tumor cells. VEGF-B was expressed in all of the benign and
malignant tumors studied, with the exception of three of eight breast carcinomas and one primary
adenocarcinoma, for which no VEGF-B mRNA was detected in Northern hybridization analysis. The
highest levels of VEGF-B mRNA were detected in primary and metastatic malignant melanomas. In a
squamous cell head and neck carcinoma sample, VEGF-B mRNA was detected via in situ hybridization in
carcinoma cells. By immunohistochemistry, VEGF-B protein was observed in the cytoplasm of cancer cells
in the six tumor samples studied expressing high levels of VEGF-B mRNA in the Northern analysis.
Endothelial cells of tumor vessels were also immunoreactive for VEGF-B, probably representing the
binding sites of diffused and endothelium-bound VEGF-B, secreted by adjacent tumor cells. Similar
findings are published for VEGF immunoreactivity in a variety of tumor tissues (Brown et al., 1993; Dvorak
et al., 1991; Salven et al., 1997a; Salven et al., 1997b). Our results suggested that VEGF-B could
contribute to tumor angiogenesis, particularly as it is known to form heterodimers with VEGF (Olofsson et
al., 1996a), which is also made by the tumor cells.
VEGF-C mRNA was detected in approximately one-half of the cancers analyzed (II). Via in situ
hybridization, VEGF-C mRNA was also localized to carcinoma cells in a squamous cell head and neck
carcinoma. All lymphomas studied contained low levels of VEGF-C mRNA, possibly reflecting the cell-
specific pattern of expression of the VEGF-C gene in the corresponding normal cells. Some of the
squamous cell carcinomas, melanomas, sarcomas, and breast carcinomas examined expressed VEGF-C
mRNA, which was also detected in one benign thymoma, whereas the other benign tumors were negative.
VEGF-C could thus be a factor regulating the mutual paracrine relationships between tumor cells and
endothelial cells in tumors and for example lymphatic vascular metastases. If lymphangiogenesis occurs in
the tumors showing the highest levels of VEGF-C mRNA, such tumors may also be predisposed to
metastatic spread via the lymphatics.
Our in situ hybridization analysis work revealed the expression of VEGF-B and VEGF-C mRNAs to be
evenly distributed in tumor cells in contrast with the previously observed highly upregulated expression
patterns for VEGF mRNA in hypoxic or necrotic tumor environments (Dvorak et al., 1995). Although
hypoxia is a stimulus for VEGF expression, similar data for VEGF-B or VEGF-C mRNAs are not reported.
In contrast, several cytokines and growth factors induce VEGF-C mRNA expression in cultured cells
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(Enholm et al., 1997), and some of them may be significant factors contributing to the expression of VEGF-
C in tumors.
In our studies, most of the tumors examined expressed mRNAs of several members of the VEGF growth
factor gene family. However, some cancers did not apparently contain amounts of the known VEGF
mRNAs. These included some ductal breast carcinomas and adenocarcinomas of the gastrointestinal tract.
In these tumors, angiogenic stimuli could be provided by angiogenic growth factors other than VEGFs. It is
also tempting to speculate that there may exist other, still unknown VEGF-related growth factors that could
be up-regulated in these cases. Additionally, the mRNA expression of the newly reported VEGF family
member VEGF-D needs to be analyzed in tumors.
Developmental stage
Receptors E7.0-E8.5 E9.0-E11.5 E12.5-E13.5 E14.5-E15.5 E16.5-E17.5
VEGFR-1
E7.5: mesoderm of
yolk sac, allantoic
bud & chorion,
amnion, blood
vessels of maternal
decidua
E9.5: yolk sac,
spongio-
trophoblast layer
of placenta
E12.5: blood
vessels and
capillaries
throughout the
embryo
E14.5:
expression in the
vacsulature
decreases
E16.5:
decreased
expression
VEGFR-2
E7-7.25:
embryonic &
extraembryonic
mesoderm
E7.5: intra-
embryonic & yolk
sac mesoderm
E9.5: allantois,
amnion, yolk sac,
venous lacunae,
endocardium,
dorsal aorta,
intersegmental
vessels
E12.5: blood
vessels and
capillaries
throughout the
embryo
E14.5:
expression is less
intensive, mostly
in vessels of the
brain, snout,
subcutaneous
tissue, limb
E16.5: still
many vessels
expressing
VEGFR-3
E8.5: angioblasts,
allantois, yolk sac,
venous lacunae,
sinusoidal veins,
giant trophoblasts
E9.0: ECs of yolk
sac & dorsal aorta
E12.5: jugular
venous sacs,
mesenterial veins,
intervertebral
vessels, axillar &
nasopharyngial
region
E14.5: lymphatic
vessels
E16.5:
lymphatic
vessels of
mesenterium,
thoracic duct
NP-1
E8.5: yolk sac,
amnion, heart,
endocardium
E9.0: heart, dorsal
root ganglios
E10.5: trigeminal
ganglion, limb bud
mesenchyme
E11.5: neocortex,
mesenchymal cells
surrounding
symphatetic
ganglia, blood
vessel endothelia
E12.5: spinal cord,
heart myocytes and
capillaries,
olfactory
epithelium, dorsal
aorta
E13.5:
hippocampus/
telencephalon
E14.5:
capillaries,
retinal ganglion
cells
E17.5: dorsal
root ganglion
neurons
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Developmental stage
Growth factors E7.0-E8.5 E9.0-E11.5 E12.5-E13.5 E14.5-E15.5 E16.5-E17.5
VEGF
E7.0: extra-
embryonic &
embryonic
endoderm
E9.0: yolk sac
endoderm,
allantois,
myocardium, gut
endoderm
E12.5: cephalic
mesenchyme,
neural ectoderm
E14.5: endocrine
glands,
diencephalon
E16.5:
gastrointestinal
tract, olfactory
lobe, choroid
plexi, kidney
VEGF-B
E8.5: allantois,
amnion, yolk sac,
head mesenchyme,
heart, neuronal
tube
E10: myocardium,
mesenchyme in
anterior part of
vertebrae,
myotomal
component of
somites
E12.5: smooth
muscle cells of
large vessels,
choroid plexi,
nasopharyngial
area, cerebellum,
tongue, ocular
muscles, Meckel’s
cartilage
E14.5: heart,
diaphragm,
choroid plexi (-),
mesenterium,
midgut, cerebral
cortex
E15.5: skeletal
muscles,
perichondrium
E16.5: heart,
muscles of
thoracic trunk,
diencephalon,
brown fat,
spinal cord,
tongue
E17.5: brown
fat, cortex of
adrenal gland
VEGF-C
E7.0: (by
Northern)
E8.5:
mesodermally
derived cells of
aortal region and
yolk sac, allantois,
cephalic
mesenchyme
E10.5:
mesenchyme
around nasal
chambers, neck &
mandible
E11.5: palatal
shelf, mesenchyme
in axillar region,
dorsal aorta
E12.5:
mesenchyme of
metanephric,
jugular, neck &
vertebral area,
periorbital tissue
E14.5: palatal
shelf, mandible,
nasal cavities,
mesenchyme of
the gut, area
surrounding
jugular area &
root ganglios,
cartilage of ribs,
hindlimb
E16.5:
subcutaneous
tissue of
hindlimb,
palate, jugular
area,
surrounding
intervertebral
arteries and
veins
(signal
downregulated)
VEGF-D
E8.5: faint
expression in head
mesenchyme, some
cells in proximity
of venous lacunae
E10.5: intrasomital
mesenchyme,
forelimb bud, nasal
process,
mandibular
component,
mesonephric area
E12.5: atrio-
ventricular bulbar
cushion tissue,
lung,
nasopharingial
area, pancreatic
primordium,
choroid plexi
E13.5-E14.5:
lung, surrounding
incisor tooth and
aorta,
nasopharyngial,
jugular, neck &
vertebral
mesenchyme,
E15.5-E16.5:
subcutaneous
tissue, lung,
tongue, linnings
of adrenal
pancreatic
primordium,
hindlimb
Organs and tissues of most intensive expression of VEGFRs, NP-1 and VEGFs, at several
time points during mouse embryonic development.
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SUMMARY AND CONCLUDING REMARKS
The heterogeneity of endothelial cells in different vessel structures involving both blood and lymph vascular
systems has developed in order to meet specialized morphological and functional requirements. VEGFR-3
is used as a specific antigenic marker for lymphatic endothelial cells in humans. Antibodies against
VEGFR-3 can prove useful for differential diagnosis of tumor lesions derived from lymphatic or the blood
vascular endothelium. Evaluation of lymphatic capillaries in tumors is difficult due to their collapsed and
attenuated morphology as well as the lack of specific markers directed against only lymphatic endothelial
cells.
Establishment of the expression profiles for VEGF-B, VEGF-C and VEGF-D sheds light on the possible
roles they may play in vivo. Localization of their mRNAs in embryos reveals the cells producing these
factors, and makes possible a comparison with the expression sites of their specific receptors in vivo, in
order to discover possible paracrine modes of action. Binding studies of these ligands, performed here for
their specific receptors using tissue sections, are of importance since they suggest that the in vitro
specificities are also maintained in vivo at different stages of development and adult life. Additional binding
studies using the same ligands also need to be performed under specific conditions such as angiogenesis
during wound healing, or in several pathological situations such as tumor growth.
The isolation of VEGF-C and VEGF-D, which both activate the lymphatic endothelial receptor VEGFR-3,
raises the possibility of tumor lymphangiogenesis, especially in tumors which highly express these factors.
The question of lymphatic proliferation in tumors remains open and puzzling with very little attention given
to the lymphatic vascular system in the absence of molecular markers. Lymphatic vessels have been
neglected and their existence in tumors has been doubted. Despite their involvement in tumor metastasis,
very little is known about the relationship between tumor cells and the lymphatic endothelium.
As a conclusion, this study has shed some light on the roles of VEGF-B, VEGF-C and VEGF-D and their
receptors in vivo. Their localization pattern in vessels of specific organs suggests that they function through
binding to adjacent receptors acting locally in a paracrine manner. The binding experiments reveal that the
mode of action of VEGF and VEGF-C is by binding to their receptors in partially overlapping vessel sites
during embryonic development, and in more distinct structures, in adult life. This is consistent with the
specific vasculogenic, angiogenic and lymphangiogenic roles that they are believed to play during
development. In the near future, generation of VEGF-C and VEGF-D mutant mice should reveal their
biological roles.
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